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Abstract
Protein Kinase C (PKC) has been implicated in many cellular responses.
Of the 11 isotypes in this family, seven are expressed in B16 mouse melanoma
cells − PKCα, PKCδ, PKCε, PKCθ, PKCλ, PKCζ, and PKCµ.

Treatment of B16 cells with retinoic acid (RA) results in growth inhibition
and differentiation. Simultaneously, RA induces a 6-8 fold increase of PKCα
protein level, but only about 2-fold increase of PKC enzyme activity. The overexpression of wild type PKCα in B16 cells mimicked the action of RA. The overexpression of enzymatically inactive PKCα, either open or closed conformation,
also inhibited B16 cell anchorage-dependent and –independent growth. The
percent reduction in growth rate correlated with the expression level of
enzymatically inactive PKCα. The over-expression of enzymatically inactive
PKCα did not affect the phosphorylation status of other PKC isozymes expressed
in B16, suggesting that it was not interfering with their functional activity.
Bisindolylmaleimide, a selective PKC enzyme inhibitor, did not reverse the effect
of RA on B16 cell growth and differentiation. Cumulatively, these data suggest
that PKCα has a non-enzymatic function in an RA-mediated cell signaling
pathway which results in growth arrest and differentiation.

PKCλ and PKCµ protein levels were decreased about 50% after 48h of
RA treatment. PKCλ protein level was found directly correlating with the growth
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rate of B16 cells. In order to study the function of PKCλ, the full length mouse
PKCλ cDNA was cloned and expressed in B16 cells. The anchorage-dependent
growth rate of B16 cell clones that over-expressed PKCλ was greater than wild
type cells. These data indicate that PKCλ may be part of a pathway leading to
enhanced B16 cell proliferation. There are no consistent changes in the levels of
cell cycle regulatory proteins in B16 cell clones which overexpress PKCλ.
However, the protein level of cyclin-dependent kinase inhibitors p21 was
downregulated and p27 upregulated by RA treatment. The p27 protein level was
increased at 2-h after RA treatment. Future studies need to investigate how p21
and p27 are regulated by RA, and to elucidate the role of PKCλ in growth control
using inducible dominant-negative PKCλ constructs.
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Literature Review
Retinoids
Retinoid is a generic term for vitamin A and its natural products or
synthetic analogs. Retinoids are a class of compounds consisting of four
isoprenoid units joined in a head-to-tail manner. The structure of retinoids can be
divided into three moieties: a polar terminal end, a conjugated side chain, and a
β-ionone ring (cyclohexenyl). There are three major endogenous retinoids: retinol,
retinal and retinoic acid (Figure 1). Retinoic acid is the most biologically active
form of retinoids. In plants, the carotenoids precursors of Vitamin A are most
often found in dark orange-colored and yellow-colored fruits and leafy greens. In
animals, Vitamin A exists as esters in liver, egg yolks, milk and milk products.
Most retinoids are fat-soluble and retinol metabolites occur in the all-trans
configuration. The 11-cis aldehyde form, 11-cis retinal, is the chromophore in the
retina of the eye, and several acid forms such as the all-trans, 3,4-didehydro- and
9-cis retinoic acids, are biologically active metabolites of retinal found in most, if
not, all tissues.

Retinol and its derivatives are hydrophobic compounds that are unstable
in the presence of oxygen and in an acidic environment yield a mixture of
dehydrated and double-bonded rearranged products. Light also catalyzes
double-bond isomerization of most retinoids. These properties require that
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retinoids be handled experimentally in an inert atmosphere, avoiding contact with
acids and protected from light.

2

Figure 1. Structure of retinoids. The upper pannel shows the structure of RA of
different configuration, all-trans and 9-cis RA. The bottom panel shows the
convesion between the three forms of retinoids, retinol, retinal, and retinoic acid.
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Figure 1

COOH
9-cis-Retinoic acid
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Transportation and metabolism
Mammals, including humans, can not synthesize retinoic acid de novo.
Vitamin A is absorbed as retinol by hydrolysis of retinyl esters or carotenoids.
The retinol is absorbed in intestine and stored in liver stellate cells as retinyl
esters (Blomhoff et al., 1990). When retinol replenishment is required, the retinyl
ester is hydrolyzed, bound to retinol binding protein (RBP) and released into the
plasma. During circulation the retinol: RBP (Yamada et al., 1987) form a complex
with the plasma protein transthyretin, previously referred to as pre-albumin. The
mechanism of the uptake of retinol from plasma into cells is not fully understood.
Inside the cells, retinol binds to cellular retinol-binding protein (CRBP) (GodovacZimmermann, 1998). CRBP has two subtypes, CRBPI and CRBPII. CRBPI is
widely distributed in a variety of different tissues including liver, kidney, lung,
testis and epididymis (Ong et al., 1982; Porter et al., 1983), while CRBPII is
localized primarily to the small intestine (Li et al., 1986). CRBPII is thought to
function as the initial acceptor of retinol entering a target cell. CRBPII has been
demonstrated to bind the luminal retinol during the process of intestinal
absorption of vitamin A.

In the target cells, retinol is converted to retinoic acid by two steps. First,
retinol is oxidized to retinal, a reaction catalyzed by several different forms of
alcohol dehydrogenases (Deuster, 1998). In the second step retinal is oxidized to
all-trans retinoic acid through the action of one of the three related retinaldehyde
dehydrogenases. This reaction is the rate limiting step in the biosynthesis of all-
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trans retinoic acid. Retinoic acid is bound to the cellular retinoic acid-binding
protein (CRABP) (Shubeita et al., 1987). The CRABPs protect retinoids in vivo
from other cellular proteins, transform bound retinoids into specific biological
compounds, and modulate the concentration of free retinoic acid available to the
nuclear receptors (Fiorella et al., 1993). There are also two subtypes of CRABP, I
and II. Both CRABPs specifically bind all-trans retinoic acid and have much lower
affinity for either retinol or retinal (Jetten and Jetten, 1979; Bailey and Siu, 1988).
CRABPI has the ability to bind 13-cis retinoic acid while CRABPII can not.
CRABPII can be induced by retinoic acid. Durand et al. (1992) demonstrated that
there is a retinoid nuclear receptor binding site in the promoter region of CRABPII.
CRABPII also may function as a ligand-dependent transcription regulator of the
RAR signaling pathway in eukaryotic cells (Delva et al., 1999).

Functions and clinical application
Vitamin A in higher animals has two very different functions, light
absorption for vision (Wald, 1951) and gene regulation for growth and
development (Maden, 1994; Hofmann and Eichele, 1994). The retinoid needed
for vision is the aldehyde isomer 11-cis retinal. RA plays a vital role in normal
embryonic development. It was shown half a century ago that conceptuses of
vitamin A-deficient rat displayed a large number of congenital abnormalities,
including the eyes, myocardium and aorticopulmonary septum, diaphragm,
respiratory and uro-genital systems (for review, see Wilson et al. 1953).
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Epidemiological evidence shows an inverse relationship between vitamin
A levels and incidence of specific malignancies (reviewed in Hong et al., 1994).
Retinoids, as anti-cancer agents, have been found to work well in some kinds of
hematological malignancies, especially acute promyelocytic leukemia, in which
RA-treatment results in the remission of the malignancy (Chomienne et al., 1996).
Moreover, retinoids have been used in a number of preclinical and clinical trials
for treatment and prevention of cancers of the skin, head and neck, lung, breast,
ovary, and prostate. All-trans RA, 13-cis RA, and the synthetic retinoid N-(4hydroxylphenyl) retinamide (4-HPR) have been used as chemo-preventive
agents for carcinoma in the aerodigestive tract and for the treatment of
leukoplakia (Lotan, 1994; Lotan et al., 1995; Hong et al., 1995 and 1987). Clinical
trials reveal that retinoids are active in reducing some second primary cancers.
For example, 13-cis-retinoic acid reduces the development of primary
aerodigestive tract tumors in patients with resected head and neck cancers
(Hong et al., 1990). Retinoids have been successfully used in combination with
interferon-α-2A, in the treatment of squamous cell carcinoma of the skina or
cervixb, and renal cell cancer (Lippman et al., 1992 a and b; Motzer et al., 1995).

Despite successful use of retinoic acid, acquired RA resistance is very
common in patients treated continuously with RA for acute promyelocytic
leukemia. Vitamin A-associated toxicities limit chronic administration of retinoids
to individuals at high risk for cancer development (Hong et al., 1986; Hong et al.,
1990). β-carotene, which is well tolerated when administered chronically, is
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unable to reduce lung cancer in high risk groups in randomized trials (Hennekens
et al., 1996; Omenn et al., 1996). The resistance to retinoic acid could be due to
decreased uptake by the cells, increased cytoplasmic sequestration, increased
cytoplasmic retinoic acid catabolism, decreased nuclear transport, or aberrations
of RA nuclear receptor-gene response mechanisms (reviewed by Gallagher,
2002). However the overall clinical efficacy of retinoic acid makes it more
important to explore the molecular mechanism of retinoic acid as a treatment and
prevention agent.

Molecular mechanism
The actions of RA are mediated by two classes of nuclear receptors, both
of which belong to the nuclear hormone receptor superfamily (Chambon, 1995).
The two classes of receptors are retinoic acid receptors (RAR) and retinoid X
receptors (RXR). Both RAR and RXR have three subtypes, α, β, and γ. Each of
these is expressed as several different isoforms due to alternative splicing,
differential promoter usage or use of more than one transcriptional start sites
(Kastner et al., 1990; Leroy et al., 1991; Leid et al., 1992; Nagpal et al., 1992).
The distribution of each RAR subtype during embryonic development is different
(Dolle et al., 1989; Ruberte et al., 1991), which suggests separate functions
among RARs.

RAR and RXR are ligand-activated transcription factors and share a
common structure which consists of six domains (designated as A to F from N-
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terminus to C-terminus) (Mangelsdorf et al., 1990; Mangelsdorf et al., 1992;
Petkovich, 1992). The A and B domains function in ligand-independent
transcription transactivation domain, while the E domain provides liganddependent transcription transactivation. Both the C and E domains have been
demonstrated to mediate receptor dimerization (Chambon, 1996). The DNA
binding domain (C domain) and ligand binding domain (E domain) are highly
conserved. The hinge region (D domain) and the carboxyl-terminal region (F) are
variable. The DNA binding domain has two zinc fingers which interact with
retinoid response elements (RARE) on the target genes (Berg, 1989; Klug and
Schwabe, 1995).

Members of the nuclear receptor superfamily modulate gene expression
by binding as homo- or hetero-dimers to specific DNA sequences. RAR functions
as a heterodimer with RXR; RXR can form homodimers or heterodimers with
many other nuclear receptors such as the vitamin D receptor (Yu et al., 1991)
and the Peroxisomal Proliferator Activated Receptors (PPAR) (Kliewer et al.,
1992). The homo- or heterodimers RAR and RXR bind to a specific DNA
sequence, RARE (retinoic acid receptor response element), found in target
genes. RARE consists of a direct repeat of PuGGTCA sequences separated by
one or five nucleotides. The RARs are activated by both all-trans RA and 9-cis
RA, while RXRs are activated only by 9-cis RA. The human and mouse RARβ2
isoform gene contains a RARE in its promoter region, so its expression is
induced by retinoic acid (Mendelsohn et al., 1991).
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The observation that unliganded RAR and thyroid receptor can strongly
transrepress target gene transcription led to the discovery of the corepressors,
such as nuclear receptor corepressor (NcoR) (Seol. et al., 1995) and silencing
mediator of retinoid and thyroid hormone receptors (SMRT) (Ordentlich et al.,
1999). The corepressors recruit a multiprotein complex with histone deacetylase
activity that modifies chromatin to prevent transcription (Alland et al., 1997).
Ligand binding induces a conformational change in the receptor protein which
causes dissociation of the corepressors and allows coactivators to bind to the
heterodimers (Chen and Evans, 1995). The coactivators such as CREB-binding
protein (CBP) and p300 possess histone acetyltransferase activity which
“relaxes” the chromatin structure allowing for transcription activation of the target
genes (Chakravarti et al., 1996; Korzus et al., 1998). This process is illustrated
in Figure 2.
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Figure 2. Metabolism, transportation, and molecular mechanism of
retinoids. When retinol is released into blood, it binds to retinol binding protein
(RBP) and is uptaken by the cells. In cytoplasm, retinol binds to cellular retinol
binding protein (CRBP), and is converted to retinoic acid. Retinoic acid binds to
cellular retinoic acid binding protein (CRABP), is transported into nucleus. In the
nucleus, retinoic acid binds to retinoic acid receptor: retinoid X receptor (RAR:
RXR) complex, which dissociates the corepressors from RAR: RXR complex and
recruits coactivators and histone acetyltransferase, and then turn on the
expression of the target gene which has a RARE in its promoter.
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Figure 2
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Retinoic acid chemoprevention mechanism
Although retinoids have been widely studied, some of their actions are not
yet fully understood. Retinoids inhibit growth of a variety of neoplastically
transformed cells by growth arrest at the G1 phase of the cell cycle (Wu et al.,
1997), promotion of differentiation (Breitman et al., 1980; Edward et al., 1988),
and initiation of apoptosis (Mangiarotti et al., 1998). No single common
mechanism of retinoid action has been identified. Abnormalities of the retinoid
signaling pathway have been identified as contributing factors to the genesis of
several human cancers (de Thé et al., 1996). The retinoic acid receptors are
essential components mediating the anticancer effects of retinoids in some
malignant cells. Low expression level of RARβ has been found in many
malignant cells, and the expression of RARβ can be induced by retinoid
treatment in retinoid-sensitive cancer cells (Sun et al., 2000). Loss of RARβ
expression is an early feature in the genesis of breast cancer and squamous cell
carcinoma of lung. Over-expression of exogenous RARβ inhibits growth and
restores retinoid sensitivity in cervical (Sun et al., 2000), lung (Liu et al., 1996a),
and breast cancer cells (Geisen et al., 2000). Over-expression of RARα and γ in
neoplastic epidermal cells causes retinoic acid-induced growth arrest and
apoptosis (Hatoum et al., 2001). Retinoic acid modulates the cell cycle through
its ability to modulate the protein levels of various cell cycle regulators. Cell
progression depends on the complexes composed of cyclins and cyclindependent kinases (cdks). Retinoic acid regulates the activities of cyclin-cdk
complexes either by destruction of cyclins through ubiquitination (Spinella et al.,
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1999), or by increasing the protein levels of the cdk inhibitors, such as p21, p27,
and p16 (Zhang et al., 2000; Dimberg et al, 2002; Arany et al., 2003). Retinoic
acid treatment induces the transcription of p21, which has a RARE in its
promoter region (Liu et al., 1996b). There is increased expression of p27 and
decreased activity of cdk2, cdk4 by retinoic acid treatment in several cancer cell
lines, including human hepatoma cells (Suzui et al., 2002) and lung cancer (Hsu
et al., 2000). The up-regulation of p27 by retinoic acid is not at the transcriptiontranslation level, but rather due to down-regulation of degradation through the
ubiquitination mechanism (Spinella et al., 1999). Constitutive expression of a
degradation-resistant mutant of cyclin D1 blocks retinoic acid-mediated growth
arrest and differentiation of an embryonal carcinoma cell line (Spinella et al.,
1999).
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Protein Kinase C
Protein

kinase

C

(PKC)

is

a

family

of

homologous

protein

serine/threonine-specific protein kinases which has been implicated as key
messengers in cell signaling. The PKC family consists of at least 12 isozymes
which can be divided into 3 subfamilies based on their homology and sensitivity
to activators. The classical PKCs (α, β1, β2, and γ) require calcium,
phospholipids, and diacylglycerol (DAG) or phorbol esters for activation. The
novel PKCs (δ, ε, η, and θ) require phospholipids and DAG/phorbol esters, but
do not require calcium for activation. The atypical PKCs (ζ and λ) are insensitive
to DAG, phorbol esters, and calcium, but require phospholipids for activation.
Finally, PKCµ, part of the PKD family, does not fit into any of these groups. It is
phospholipid-dependent, calcium-insensitive and activated by phorbol esters.
However, its catalytic domain is divergent from that of PKC family members.

Structure of PKC
Members of the protein kinase C family consist of a single polypeptide.
The N-terminal region of the protein contains the regulatory domain and the Cterminal region contains the catalytic domain. Classical PKCs (cPKC) contain
four conserved domains C1-C4 (Fig. 3). The C1 domain contains the cysteinerich motif (zinc finger motif), duplicated in most isozymes, which forms the
binding sites for phospholipids and DAG. This domain is immediately preceded
by the pseudo-substrate (PS) site, which has a high affinity for the active site of
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the kinase and thereby inhibits enzyme activity by preventing substrate
interaction. Mutation of this site leads to activation of PKC (Pears et al., 1990).
The C2 domain is the calcium-binding domain. C1 and C2 together regulate the
kinase activity. Because of the existence of both C1 and C2 domains in cPKCs,
the cPKCs respond to phospholipids, phorbol esters and calcium. The C3 and C4
domains together constitute the catalytic domain, with the ATP-binding site
located in the C3 domain and the protein substrate recognition site located in the
C4 domain. The novel PKCs (nPKCs) are structurally similar to the cPKCs,
except for the C2 domain. This domain in nPKCs maintains the structural
similarities, but does not have the functional groups that mediate calcium binding.
Therefore the nPKCs only respond to phospholipids and phorbol esters, but not
calcium. The atypical PKCs (aPKCs) are structurally quite different from the other
two subfamilies. First, the C1 domain of aPKCs has only one cysteine rich motif,
and second, cPKCs lack a C2 domain. Protein kinase Cµ (PKCµ) or its mouse
homologue protein kinase D (PKD) differs from PKC isozymes by its N-terminal
signal peptide (SP), transmembrane domain, and pleckstrin homology (PH)
domain in the regulatory region. The regulatory domain serves two key functions;
(i) it targets the kinases to the appropriate cellular location; and (ii) it regulates
kinase activity by serving as an autoinhibitory module.
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Figure 3. Structure of PKC isozymes. PKC is a single polypeptide. It consists
of the regulatory domain in the N-terminus, the catalytic domain in the C-terminus,
and the hinge region between these two domains. The catalytic domain of all
PKCs has C3 and C4 domains. The conventional PKCs (cPKCs) and novel
PKCs (nPKCs) have pseudostrate site, C1 domain and C2 domain in the
regulatory domain. The C1 domain of cPKCs and nPKCs has two cysteine-rich
motifs. The atypical PKCs (aPKC) have psudosubstrate site and C1 domain in
the regulatory domain, and the C1 domain only has one cysteine-rich motif. The
regulatory domain of PKCµ consists of transmembrane domain, peudosubstrate
site, C1 domain, and pleckstrin homology. N – N-terminus of the protein; C – Cterminus of the protein; PS – pseudosubstrate site; C – conservative domain;
SP/TM – signal peptide/transmembrane domain; PH – pleckstrin homology.
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Figure 3
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Activation of PKC
PKC activation is regulated by phosphorylation and interaction with
cofactors. Phosphorylation is important in the activation of PKC family members.
Full kinase activity depends upon phosphorylation of their catalytic domain
activation loops. The highly conserved threonine residue in the activation loop
must be phosphorylated before the kinase can phosphorylate its substrate. The
phosphorylation

of

this

threonine

then

leads

to

the

subsequent

autophosphorylation of serine/threonine at two C-terminal sites: the turn motif
and the hydrophobic motif, which is roughly about 160 amino acids carboxyterminal to the activation loop phosphorylation site (Behn-Krappa and Newton,
1999; Cenni et al., 2002). The kinase capable of phosphorylating the activation
loop site in PKC was discovered to be 3-phosphoinositide-dependent kinase 1
(PDK-1). PDK-1 has been shown to be the upstream activating kinase for
conventional (Dutil et al., 1998), novel (Le Good et al., 1998; Cenni et al., 2002)
and atypical (Le Good et al., 1998; Chou et al., 1998) PKC family members.
PDK-1 was first found to phosphorylate protein kinase B (PKB)/Akt. PKB/Akt
becomes a substrate for PDK-1 once its PH domain engages PIP3 on the
membrane, exposing the PDK-1 phosphorylation site. The naming of PDK-1
reflects

the

Nonetheless,

phosphoinositide-dependence
the

phosphorylation

of

of

PKC

its
by

first
PDK-1

known

substrate.

appears

to

be

phosphoinositide-independent (Sonnenburg et al., 2001). The intrinsic activity of
PDK-1 appears to be constitutive. The fully phosphorylated PKC is competent to

19

be activated by the lipid second messengers. The interaction of DAG with the C2
domain dissociates the pseudosubstrate sequence from the substrate-binding
site, and the conformational change allows full enzymatic activity. The unmasking
of the substrate-binding site allows substrate to bind and become phosphorylated.

Degradation of PKC
Active PKC is highly sensitive to dephosphorylation. Dephosphorylated
PKC is ubiquitinated and subsequently degraded in the proteosome (Lee et al.,
1996). Prolonged activation by phorbol esters results in the down-regulation of
cPKCs and nPKCs through this proteolytic pathway. Atypical PKCs are resistant
to this phorbol ester-induced down-regulation.

Distribution and Translocation of PKC
Translocation of PKCs was once taken as the hallmark of PKC activation.
The localization of PKCs determines their function and specificity. Most PKCs are
located in the cell cytosol in the inactive state, although individual PKCs have
their own distribution patterns. PKCα localizes in the cell homogenously and
translocates to the cell membrane and perinucleus upon activation by phorbol
esters. Receptor for activated kinase C (RACK) and other PKC binding proteins
are involved in the determination of the location and substrate specificity of PKC
isozymes (Mochly-Rosen, 1995).
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Functions of PKCs
PKCs have been implicated in the control of cell proliferation,
differentiation, and survival in many tissue types. Abnormal PKC activity is
involved in cardiovascular, pulmonary, allergic, mental and other disorders.
However, the specific role of individual PKC isozymes in carcinogenesis is not
clear. The PKC isozymes may play opposite roles (Mandil et al., 2001). The
action of the same isozymes in different tissue types may also be different. For
example, in the intestine, PKCα has been shown to be a key regulator for the
induction of cell cycle withdrawal of the intestinal epithelium, and expression of
PKCα is down- regulated in APCmin mouse adenoma and sporadic human colon
adenocarcinomas (Klein et al., 2000). In contrast, in some human breast
carcinomas, the expression of PKCα is up-regulated compared to the adjacent
normal tissues (O’Brian et al, 1989).

Individual PKC isozymes
Mammalian PKCα consists of 672 amino acids and is about 81 KDa in
molecular weight. PKCα is ubiquitously expressed, and is activated by stimuli
such as signals activating tyrosine kinase receptors, physical stresses and
mechanical strain. Upon stimulation, PKCα translocates from cytosol to specific
cell compartments, including nuclei, focal adhesions, and regions of cell-cell
contact (Wagner et al., 2000; Ng et al., 1999). One of the compartments PKCα
translocates to is the nucleus (Buchner, 1995). Since PKCα does not have a
nuclear localization signals (NLS), it is unclear how PKCα translocates to the
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nucleus (Schmalz et al., 1998). As mentioned previously, the isoform-specific
anchoring proteins (RACK) are important in conducting the isozyme-specific
localization and different functions. The anchoring proteins responsible for PKCα
in focal adhesions are vinculin and talin in REF52 cells (Hyatt et al., 1994), and
β1-integrin in MCF-7 cells (Ng et al., 2001). However, the protein anchoring
PKCα within the nucleus is not known. PKCα is implicated in many biological
responses, such as proliferation, apoptosis, differentiation, cell migration,
adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, and inflammation.
The biological responses of PKCα are cell-type specific. For example,
overexpression of PKCα promoted MCF-7 human breast cancer cells to a more
aggressive phenotype (Ways et al., 1995), while overexpression in human
intestinal epithelial cells induced withdrawal from the cell cycle (Frey et al., 2000).
The mechanism of PKCα action is not very clear. The proliferative effect of PKCα
appears to be related to the activation of the extracellular signal-regulated
kinase/mitogen-activated protein kinase (ERK/MAPK) cascade initiated by Raf-1
(Kolch et al., 1993). The cell cycle arrest mediated by PKCα may be due to the
accumulation of retinoblastoma protein (Rb) and induction of the cyclin
dependent kinase inhibitors, p21Cip1 and p27Kip1(Slosberg et al., 1999; Frey et
al.,1997; Frey et al., 2000).

The PKCβ gene generates two proteins, PKCβI and PKCβII, by alternative
splicing of the C-terminal exons (Ono et al., 1987).

PKCβI and PKCβII are

mainly involved in the immunoreceptor and insulin receptor signaling pathways
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(reviewed by Kawakami et al., 2002). PKCγ is exclusively expressed in the
central nervous system. PKCγ is implicated in long term depression and other
mental disorders (reviewed by Saito and Shirai, 2002). PKCθ is expressed at
high levels in T lymphocytes and muscle. PKCθ plays essential roles in T cell
activation and the T cell receptor-linked signaling pathway mediating T cell
activation (Altman et al., 1990; Isakov and Altman, 2002). PKCε regulates
various physiological immune functions. PKCε is also implicated in some disease
states including malignancies, diabetes, cardiac ischemia, and Alzheimer’s
disease (reviewed by Akita, 2002). PKCδ seems to be linked to proliferation
control. Overexpression of PKCδ results in growth arrest of cancer cells
(Watanabe et al., 1992; Fukumoto et al., 1997), and apoptosis of prostate cancer
cells (Sumitomo et al., 2002). The expression of PKCη is also tissue-specific; it is
expressed predominantly in squamous epithelia, including skin, tongue,
esophagus, forestomach, trachea and bronchus. The expression level of PKCη
increases with differentiating or differentiated cells, and overexpression of PKCη
results in the hyperdifferentiation of squamous cells. Therefore, PKCη plays a
crucial role in squamous cell differentiation (Denning et al., 1995; Kuroki et al.,
1999).

Although PKC isozymes are widely involved in cell responses in a celltype specific, temporal and spatial manner, surprisingly PKC isozyme knockout
mice appear to be functionally normal in regard to external characteristics,
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viability and fertility (Leitges et al., 2002). The only exception is the PKCλ
knockout mouse, which is embryonic lethal.

PKCλ was first cloned by Dr. S. Ohno’s group in 1994 (Akimoto et al.,
1994). PKCλ bears a high similarity (72%) in amino acid sequence with another
member of aPKCs, PKCζ.

PKCι, which has 98% identity with PKCλ, is the

human homologue of murine PKCλ. Due to its N-terminal structure, PKCλ, like
PKCζ, is insensitive to calcium, DAG, and phorbol esters in vitro and in vivo.
However it can be directly activated by lipid second messengers, such as
ceramide, PIP3, and phosphatidic acid. Unlike the cPKCs and the nPKCs,
aPKCs contain glutamic acid instead of the second autophosphorylatable serine
in the C-terminal hydrophobic motifs (Newton, 2001). It has been shown that
PKCλ is involved in embryogenesis and other physiological processes including
glucose transportation and growth. There are several proteins that interact with
PKCζ and modify its action (Figure 4). Several proteins that interact with the V1
region of aPKCs share a small acidic stretch called AID (atypical PKC-interacting
domain). These proteins are p62, Par-6 (partitioning-defective-6), and MEK5.
The selective aPKC binding protein, p62, bridges PKCλ with RIP, which is a
scaffold protein in the tumor necrosis factor-α (TNFα) signaling pathway. Thus
PKCλ is involved in the transduction of TNFα signaling, which leads to the
activation of nuclear factor-κB (NF-κB) (Sanz et al., 1999). The α isoform of the
kinase MEK5, which interacts with aPKCs through its AID, brings aPKC into the
control of cell growth by regulating its downstream kinase BMK1/Erk5 (English et
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al., 1998; Kamakura et al., 2000). Par-6 is one of the conserved cell polarity
proteins named after a C. elegans partition defective mutant. The PKCλ-Par6
complex interacts with Par3, an aPKC specific interacting protein (ASIP), which
also interacts with the C-terminus of a transmembrane component of the tight
junction, thereby controlling cell polarity (Ebnet et al., 2001; Suzuki et al., 2001).
The expression level of PKCλ is high in undifferentiated cells, and then
decreases with cell differentiation. There is also evidence that PKCλ is a prosurvival factor. Over-expression of the von Hippel-Lindau tumor-suppressor
protein increases the ubiquitination of PKCλ, leading to the down-regulation of
PKCλ (Okuda et al., 2001). Also the induction of cyclin D1 by oncogenic Ha-Ras
requires PKCλ. Another PKCλ interacting protein, Par-4 (prostate androgen
response-4), is an inhibitor of PKCλ activity. Overexpression of Par-4 causes
cells to undergo apoptosis as a result of its ability to inhibit aPKC activity (DiazMeco et al., 1996). Despite their similarity in amino acid sequence, the functions
of PKCλ/ι and PKCζ are not redundant. PKCζ knockout mice are viable showing
impaired NF-κB signaling and immune responses, while PKCλ/ι knockout mice
die at an early embryonic stage (Leitges et al., 2001; Martin et al., 2002).
Lambda interacting protein (LIP) has shown specifically to interact with the zinc
finger domain of PKCλ/ι, but not PKCζ (Diaz-Meco et al., 1996). This interaction
stimulates PKCλ kinase activity following the mitogen stimulation of quiescent
cells.
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Figure 4. Protein kinase Cλ structure and physiological function mediated
by interacting proteins. PKCλ binds to Par-6 (partitioning-defective-6) and the
PKCλ-Par6 complex interacts with Par3. The PKCλ-Par6-Par3 complex and
involved in cell: cell junctional structure and the establishment of cell polarity.
Through interaction with p62, PKCλ is involved in the TNFα (tumor necrosis
factor α) signaling pathway, and the following activation of nuclear factor-κB (NFκB). The interaction with MEK, brings PKCλ in the MAPK signaling pathway. LIP
(lambda interacting protein) activates PKCλ activity and Par-4 (prostate androgen
response-4) inhibits PKCλ activity.
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Figure 4
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Melanoma
Skin cancer is the most common malignancy and accounts for half of
the newly diagnosed cancers in the western population. The incidence of skin
cancer has risen significantly in the last decade. There are three kinds of human
skin cancer: malignant melanoma, basal cell carcinoma and squamous cell
carcinoma. Melanoma is the least common skin cancer, accounting for about 4%
of all skin cancer. However, it has the highest mortality of all the skin cancers. In
2002, among the 1.3 million Americans who were diagnosed with skin cancers,
56,000 individuals had melanoma, and 7,000 people died of melanoma (Geller,
2003). The annual incidence rate of melanoma in fair-skinned populations has
increased about 3-7% in the last decades (Pollock and Trent, 2000; Severi et al.,
2000; Deipgen and Mahler, 2002). Risk factors for melanoma include family
history, severe blistering sunburn, especially before the age of eighteen, fair skin,
precancerous lesions, previous melanoma, and exposure to ultraviolet radiation.
Epidemiological studies show that exposure to UV radiation is the most
significant risk factor for cutaneous melanoma (Elwood and Gallagher, 1994).
Sunburn experienced during childhood and adolescence has greater effect on
melanoma incidence than sunburn at a later age (Østerlind, 1992; Zanetti et al.,
1992).

Over 90% of primary melanoma originates in the skin. The cutaneous
melanoma arises from a melanocytic nevus which is a benign tumor of the
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pigment producing cells in the skin. The melanocytic nevus progresses to
dysplastic nevus, which is considered as the pre-malignant lesion. The dysplastic
nevus progresses to first a radial growth phase and then the vertical growth
phase of localized malignant melanoma. The frequent metastatic sites of
melanoma are lungs, brain and liver. Chromosome alterations have seen
identified in melanomas (Newton, 1997).

Genetics of cutaneous melanoma
For most cancer, tumorigenesis is a multi-step process, involving the upregulation of oncogenes and down-regulation of tumor suppressor genes. Recent
melanoma research has identified the cytogenetic and genetic alterations
responsible for the development and progression of this tumor. There are a
number of oncogenes reported to be involved in the transformation to malignant
melanomas. These genes include the signal transducers ras (Papp et al., 1999;
Bastian et al., 2000), b-raf (Davies et al., 2002; Pollock et al., 2003), cyclinD1
(Sauter et al., 2002), cdk4 (Zuo et al., 1996), c-myc (Kraehn et al., 2000), and
hdm2 (Polsky et al., 2002), growth factors bFGF (Meier et al., 2000) and
MGSA/GRO (Owen et al., 1997), and the inhibitors of apoptosis bcl-2 and bclxL(Leiter et al., 2000). Demunter et al (2001) reported N-Ras mutations in 33%
of primary and 26% of metastatic clinical melanoma samples. About 66% of
melanomas have a b-raf mutation (Davies et al., 2002). Raf can be activated by
ras, and it in turn activates the MAPK/ERK pathway. Point mutations of B-raf
often seen in melanoma increase its kinase activity and then activate the MAPK
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pathway, which confers the growth advantage to melanoma cells. Amplification of
cyclin D1 has been identified mostly in acral melanoma (Sauter et al., 2002).
Point mutations of Cdk4 interfere with its binding to p16, the cell cycle kinase
inhibitor which itself is often found mutated in familial melanomas (CannonAlright et al., 1992). Disruption of the function of tumor suppressor genes also
contributes to the process of oncogenesis. The tumor suppressor genes altered
in melanoma are PTEN and p53. PTEN, located at chromosome 10, is a gene
deleted or mutated in more than 40% of melanoma cell lines and melanoma
specimens (Guldberg et al., 1997). PTEN encodes a phosphatase which
degrades the products of PI3K by dephosphorylating phosphatidylinositol-3,4,5triphosphate (PIP3) and phosphatidylinositide 3,4-bisphosphate at the 3 position
(Simpson and Parsons, 2001). Loss of functional PTEN in tumor cells causes an
increase in Akt phosphorylation and activity, leading to decreased apoptosis
(Kennedy et al., 1997; Kulik et al., 1997). Restoration of normal PTEN expression
by transferring chromosome 10 into a PTEN-null malignant melanoma cell line,
retarded the tumor cell growth (Stahl et al., 2003). The loss of heterozygosity of
p16, a cell cycle inhibitor, may be one of the earliest events in melanoma
development, as the deletion is detected in invasive primary lesions with thin
tumor thickness (Healy et al., 1996; Rocco and Sidransky, 2001).
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Experimental Objectives
This dissertation addresses the role of PKC isozymes in retinoic acidinduced B16 mouse melanoma cell growth arrest and differentiation. Previous
studies from this laboratory have shown that PKCα is important in RA-induced
B16 cell growth arrest and differentiation. I investigated the requirement for PKCα
enzyme activity for mediating RA-induced B16 cell growth arrest and
differentiation. The first part of this dissertation describes experimental results
which address the role of PKCα.
During the study on the first part of my thesis dissertation, I discovered
that PKCλ was down-regulated by RA treatment. I also found that expression of
PKCλ correlates with B16 cell growth rate. The second part of this thesis is
focused on the role of PKCλ in the regulation of B16 cell growth. Lastly I
determined whether RA inhibits cell proliferation by altering the expression of cell
cycle regulatory proteins.
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Chapter Ι
Non-enzymatic function of PKCα in
retinoic acid-induced growth arrest
and differentiation
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Introduction
Retinoids have been shown to induce growth arrest and differentiation in a
variety of tumor cell lines, including B16 mouse melanoma (Breitman et al., 1980;
Meyskens and Fuller, 1980; Wu et al., 1997). In this mouse melanoma cell line,
RA induced a 5-8-fold increase in PKCα expression (Niles and Loewy, 1989).
Overexpression of wild-type PKCα in B16 cells mimicked the phenotype induced
by RA, including inhibition of anchorage-dependent and –independent growth
and increased melanin production. Down-regulation of PKC by chronic phorbol
dibutyrate treatment antagonizes the ability of RA to induce growth arrest and
differentiation. These data suggest that PKCα plays a critical role in mediating
the effect of RA on B16 melanoma cells. However, we show here that the PKCselective inhibitor, bisindolylmaleimide, does not block the action of RA on B16
cells. Thus it appears that PKCα might have a non-enzymatic function in the
regulation of melanoma growth. To test this hypothesis, we used two types of
PKCα mutants (Figure 5). Both have a mutation at the ATP-binding site which
inactivates the enzyme activity. One also has additional mutations in the pseudosubstrate site. This mutation prevents binding of the substrate recognition
domain and hence results in a mature “open” conformation. Normally it would
yield a constitutively active PKCα. However, the mutation at the ATP-binding site
prevents catalytic activity. When transfected into cells, this enzymatically inactive
mutated PKCα will compete with the endogenous PKCα for its substrates and
thus prevent the phosphorylation of PKCα substrates. Therefore, overexpression
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of mutant PKCα inhibits the function of endogenous PKCα. I will report in my
thesis that stable expression of these mutant PKCα proteins recapitulates some,
but not all, of the phenotypic changes found in retinoic acid treated wild type B16
melanoma cells.
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Figure 5. Structure of dominant-negative PKCα. Both PKCα mutants have
mutation at the ATP-binding site, which inactivates the PKCα. The PKCα mutant
with the only mutation at the ATP-binding site mimics the structure of inactive
PKCα and is designated as closed-conformation. When PKCα is fully activated
through phosphorylation and cofactor-binding, the pseudo-substrate site
dissociates from substrate-binding site. The two additional single mutations at the
pseudo-substrate site dissociate the pseudo-substrate site from the substrate
binding site; therefore the conformation of this PKCα mutant mimics that of the
active PKCα. This PKCα mutant with additional mutations is designated as openconformation. A - alanine, K - lysine, P – phosphate group, and R - arginine.
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Figure 5
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Materials and Methods
Cell Culture: B16 mouse melanoma cells were cultured in a humidified
atmosphere of 5% CO2, 95% air at 37°C in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Grand Island, NY). This medium contained 1 g/l glucose and
was supplemented with 10% bovine calf serum (Hyclone, Logan, UT) for most of
the experiment or 10% fetal bovine serum for growth studies in comparison with
stably transfected clones, 50 units/ml penicillin G, and 50 µg/ml streptomycin
sulfate. All the stably transfected clones were grown in DMEM medium
supplemented with 10% fetal bovine serum.

Reagents: All the reagents used in this research were obtained from
Sigma (St. Louis, MO) if not stated otherwise. The retinoic acid all-trans-RA was
obtained from Fluka Chemical Company (New York). All experiments involving
the use of RA were conducted in yellow light to prevent photo-oxidation of the
retinoids and the RA in each experiment was freshly made. Retinoic acid,
bisindolylmaleimide, and phorbol-12, 13-dibutyrate were dissolved in dimethyl
sulfoxide (DMSO) and handled in yellow light. DMSO was used as the vehicle
control. Transfer buffer was 2.5% (w/v) Tris, 1.44% Glycine, 0.1% SDS, and 20%
(v/v) methanol. TBS was 20 mM Tris pH 7.6, 0.137 M NaCl, and 0.1% Tween-20.
Electrophoresis running buffer was 1.44% Glycine, 0.3% Tris-base, and 0.1%
SDS. LB (Luria-Bertani) medium (1.0% Tryptone, 0.5% Yeast Extract and 1.0%
NaCl) was dissolved in deionized water, the pH was adjusted to 7.0 with NaOH,
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and the solution was autoclaved for 20 minutes at 15 lb/sq. inch, after which
ampicillin was added to bring the final concentration to 50 µg/ml. For LB agar
plates, LB medium was prepared as above, with the addition of 15 g/L agar
before autoclaving. After sterilization by autoclaving, ampicillin was added as
above, and the solution was then poured into 100 mm plates. When the agar was
solidified, the plates were inverted and stored at 4°C.

Transformation: 5-10 ng of plasmid DNA or 2 µl of cloning reaction was
used for transformation. DNA was introduced into competent E.coli cells by heat
shock at 42°C for exactly 30 seconds. The competent cells were purchased from
Invitrogen Life Technologies (Carsland, CA). SOB medium was added to the
mixture, and the mixture was rocked at 37ºC for 1 h. The mixture was spread
onto agar plates and incubated at 37ºC overnight. Six colonies were picked,
inoculated into LB medium and incubated at 37ºC for overnight.

Plasmid DNA isolation: Plasmid DNA was isolated using Mini-prep
Kits from Eppendorf (Brinkmann Instruments, New York) using the company’s
protocol. Briefly, transformed cells were pelleted and then solutions I, II, III were
added sequentially. Supernatant was collected and transferred to a column. DNA
was bound to the binding matrix and after washing the column to remove
contaminants, the DNA was collected in the elution buffer. The purity and
concentration of isolated DNA was determined by UV absorbance using
spectrophotometry (Beckman Coulter, Somerset, NJ). An OD260/280 ratio over
1.8 was considered acceptable quality of the DNA.
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Stable Transfection of B16 Cells: B16 cells were co-transfected with
the PKCα mutant with single mutation, SRD-PKCα-Kn (K365R) expression
vector (YK539) or PKCα mutant with additional mutations, SRD-PKCα-KnR22A/A25E) expression vector (YK563) and the pSV40-neo plasmid encoding
the gene for neomycin resistance at a 1:10 ratio (pSV40-neo: YK539/YK563).
The day before the transfection, B16 cells were seeded at 0.8 million per dish.
Transfection was accomplished by using Lipofectamine plus reagent (Invitrogen
Life Technologies). For each 100 mm plate, 4 µg of DNA were diluted in 750 µl of
serum free DMEM, 20 µl of Plus Reagent was added to the DNA and mixed
(precomplexed DNA). The precomplexed DNA was then incubated at room
temperature for 15 minutes. At mean time, 30 µl of Lipofectamine Reagent was
diluted in 750 µl of serum free DMEM, which was combined with the
precomplexed DNA. This DNA-Plus-Lipofectamine Reagent complex was
incubated at room temperature for 15 minutes. Plates of B16 cells were washed
with PBS to remove residual medium and 5 ml of serum free DMEM added. The
DNA-Plus-Lipofectamine Reagent complex was added to each plate. The plates
were incubated at 37°C, 5% CO2 for 5 hours. After the 5-hour incubation, the
volume of medium of each plate was increased to 10 ml and fetal bovine serum
was added to bring the final concentration to 10%. Neomycin-resistant clones
were selected in DMEM containing 1.43 mg/ml of the neomycin derivative G418
(Gibco BRL Life Technologies, Rockville, MD).

Western Blot Analysis: Cells were seeded at 2x105 /100mm dish.
After attachment (overnight), cells were refed with DMEM containing 10% fetal
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bovine serum with or without 10 µM RA and incubated for forty eight hours,
followed by addition of lysis buffer (62.5 mM Tris (pH 6.8), 2% w/v sodium
dodecyl sulfate (SDS), 10% glycerol, 50 mM DTT, 0.1% w/v bromphenol blue, 1
µg/ml

leupeptin,

1

µg/ml

pepstatin,

50

µg/ml

phenylmethylsulfonyl fluoride, and 0.5% Triton X-100).

aprotinin,

0.5

mM

Cell lysates were

sonicated for 10 seconds with a Tekmar sonic disruptor (Tekmar Corp.,
Cincinnati, OH) at power setting 60. Cell lysates were centrifuged at 14,000 rpm
for 5 minutes. Proteins were denatured at 100°C for 2 minutes. Equal volumes of
cell lysates were loaded into wells and electrophoretically separated on a 10%
SDS polyacylamide gels. Proteins were electrically transferred to a Hybond-C
Extra nitrocellulose membrane (Amersham). Membranes were incubated for 1
hour in blocking buffer (5% nonfat dry milk in Tris-buffered saline containing 0.1%
Tween (TBST)). The primary antibody was diluted in blocking buffer. The dilution
for monoclonal anti- PKCα and -PKCδ antibodies (Upstate Technology, Lake
Placid, NY) was 1:3000. The dilution for monoclonal anti-PKCε, -PKCη -PKCλ,
and PKCζ antibodies (Transduction Laboratories) was 1:400. The incubation time
for these antibodies was 3 hours. The dilution for anti-GAPDH antibody was
1:5000, and the incubation time was 1 hour. The dilution for anti-Erk1/2, anti-p38,
anti-phosphorylated-Erk1/2, anti-phosphorylated-p38, anti-phosphorylated-PKCα,
anti-phosphorylated-PKCδ,

anti-phosphorylated-PKCλ,

anti-phosphorylated-

PKCζ, anti-PKCµ, and anti-phosphorylated-PKCµ antibodies (Cell Signaling
Technology, Beverly, MA) was 1:1000. All the antibodies from Cell Signaling
were polyclonal antibodies and the incubation was at 4°C and overnight. Blots
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were washed 3 times in TBST, followed by an hour incubation with a 1:3000
dilution of rabbit anti-mouse horseradish peroxidase-conjugated secondary
antibody (Amersham Biosciences, Piscataway, NJ) for monoclonal primary
antibody, or goat anti-rabbit horseradish peroxidase-conjugated secondary
antibody (Cell Signaling Technology, Beverly, MA) for polyclonal primary
antibody. Membranes were washed 3 times in TBST after incubation with
secondary antibody. Reactive bands were visualized by the enhanced
chemiluminescence

method

(Amersham

Biosciences).

All

washes

and

incubations were performed at room temperature except mentioned otherwise.
The density of each band was measured by a laser scanning densitometer
(Molecular Dynamics, Sunnydale, CA).

Enzyme Activities of Partially Purified PKC: This assay system
utilizes

synthetic,

PKC-specific,

substrate

peptides

which

become

phosphorylated with the radiolabeled phosphate group from [γ-32P]ATP.Culture
conditions were the same as those described for Western blot. Cell were lysed
on ice with 20 mM Tris, pH 7.5, 2 mM EDTA, 1 mM dithiothretol, 5% Triton X-100,
0.5 mM phenylmethylsulfonyl fluoride, and 10 µg/ml aprotinin. Complete cell
disruption was further ensured by three consecutive 10-s sonication with a
Tekmar sonic disruptor at power setting 60. The total cell lysate was centrifuged
at 12,000xg for 15 min. The supernatant was loaded onto a DEAE-cellulose
anion exchange column, which was made by packing Cellex-D cellulose (BioRad Laboratories, Hercules, CA) into a 1 ml syringe. The column was preequilibrated with column buffer (20 mM Tris, pH 7.5, 2 mM EDTA, 0.5 mM EGTA,
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1 mM dithiothretol). The column was washed with 15 volumes of column buffer
containing 100 mM NaCl and the eluate concentrated with a Centricon-30®
microconcentrator (Millipore, Billerica, MA). Protein concentration of samples was
determined by the Bradford method.

Samples were diluted to equal protein

concentrations and assayed with a commercially available PKC assay kit
(Amersham Biosciences).

The reaction was initiated by addition of 25 µl of

protein sample to a reaction mixture containing 3 mM calcium acetate, 50 mM
Tris-HCl, 0.5% (w/v) sodium azide (pH 7.5), 0.075 mg/ml Lα--phosphatidyl-Lserine, 6 µg/ml phorbol 12-myristate 13-acetate, 225 µM peptide substrate, 7.5
mM dithiothretol, 200 µM magnesium [γ-32P]ATP (Amersham Biosciences), 12
mM magnesium chloride (pH 7.4), and 5 mM Hepes in a total volume of 25 ml.
After incubation for 15 min at 37°C, reactions were stopped by adding 300 mM
orthophosphoric acid. Aliquots of the reaction mixtures were spotted onto the
binding paper discs, and the discs were washed twice for 5 min in 75 mM
orthophosphoric acid for 5 min. At the end of the reaction, the radiolabeled
peptide was separated from unincorporated 32P by the use of an affinity paper for
the peptide. The degree of phosphorylation was determined by liquid scintillation
counting. Enzyme activity was calculated from counts/min taking into account the
specific activity of the radioisotope and reaction time. PKC activity was
expressed as 32P incorporated /min/mg protein.

Monolayer Growth Curves: Cells were seeded at a density of 2.8 x
104 cells/60mm tissue culture dish (Falcon, Franklin Lakes, NJ) in 3.6 ml of
DMEM containing 10% fetal bovine serum. The medium was changed on the
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second day and 10 µM retinoic acid or vehicle was added at this time. For
experiments using PDB, cells were pre-treated with PDB for 24 h and then RA
was added to the medium. RA was handled in yellow light at all times. Cells were
incubated at 37°C in 5% CO2, 95% air. At 24 h intervals, cells were harvested by
trypsinization, and cells were counted with a hemacytometer.

Colony Formation in Soft Agarose: A 3 ml bottom layer of freshly
prepared 1% agarose/DMEM/10% fetal bovine serum containing the appropriate
RA concentration was dispensed into 60 mm dishes and allowed to solidify. The
top layer consisted of 5000 cells suspended in 3 ml of 0.3% agarose/DMEM/10%
fetal bovine serum containing the respective RA concentration. Following
solidification of the top layer, a 2.5 ml DMEM/10% serum liquid overlay,
containing the appropriate RA concentration, was added to each dish. For
experiments using PDB, B16 cells were pre-treated with PDB while grown as
monolayer for 24 hours and then transferred to the top layer of agarose. The
liquid phase +/− various treatments was changed every 48 h. Viable colonies
were counted 10 days after seeding. Only colonies greater than or equal to 300
µm in diameter were counted.

Melanin Content of Media and Cells: Cells were seeded into 60 mm
dishes at different densities based on their growth rate so that after 4 days of
growth their densities would be similar. After attachment, cells were refed with
DMEM +/- 10 µM RA. Exactly 3.6 ml medium was added to each dish. Fortyeight hours after the treatment, 1.5 ml aliquots of medium were taken from each
dish and centrifuged at 12,000 × g for 10 sec. The relative melanin contents of
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supernatants were determined by measuring the absorbance at 462 nm. 800 µl
of 1 N KOH were added to each dish. Cell lysates were collected and incubated
at 80°C for 1 h. The hydrolysates were centrifuged at 12,000 x g for 10 sec. The
relative melanin concentrations of the cleared lysates were determined by
measuring the absorbance at 462 nm.

AP-1 Transcriptional Activity: Wild type B16 cells or PKCα mutantexpressing clones were co-transfected with the reporter plasmid 3.8 µg of pGL2-AP-1 DNA and 0.2 µg of SV40-β-galactosidase

DNA, to correct for

transfection efficiency. The second day after transfection, cells were split and
seeded at equal density into multi-well plates. After the attachment, cells were
treated with or without 10 µM RA for 24 h. Cells were then harvested and
assayed for luciferase and β-galactosidase activity using kits from Promega
(Madison, WI). The luminescence was measured using a Lumat (Model: LB9501,
Wallac Inc. Gaithersburg, MD).
Statistical analysis: Statistical analyses were performed using one way
ANOVA in SigmaStat™ statistical software (Jandel Scientific; San Rafael, CA).
Statistical significance was judged at the p<0.05 level.
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Results
Previous work in our laboratory has shown that treatment of B16 mouse
melanoma cells with retinoic acid results in at least a 6-8 fold increase in PKCα
mRNA and protein (Rosenbaum and Niles, 1992). Ectopic overexpression of
wild-type PKCα in B16 cells results in a phenotype (decreased anchoragedependent, -independent growth and increased melanin production) that mimics
treatment with retinoic acid (Niles and Combs, 1996). Interestingly, treatment of
these PKCα overexpressing clones with phorbol dibutyrate did not further
enhance the phenotypic change that mimicked retinoic acid treatment. Therefore
I investigated whether PKC enzyme activity was required for the phenotypic
changes induced by retinoic acid in B16 melanoma cell.
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Effect of PKC enzyme inhibitor bisindolylmaleimide on B16 cells: Figure 6
shows that combining bisindolylmaleimide, a PKC enzyme inhibitor (with higher
specificity for conventional PKCs such as PKCα) with retinoic acid did not alter
the ability of this retinoid to inhibit anchorage-dependent (Figure 6A) and –
independent growth (Figure 6B) when compared to cells treated only with retinoic
acid. RA alone induced a 50% decrease in B16 cell anchorage-dependent
growth at 48 h. Bisindolylmaleimide and RA together induced a further decrease
(30% to 60%) in growth compared to RA alone. Interestingly, treatment of B16
cells with only the PKC enzyme inhibitor resulted in a dose-dependent inhibition
of proliferation and soft agarose colony formation (anchorage-independent
growth) compared to untreated control cells (Figure 6B). Similarly, inhibition of
PKC enzyme activity alone increased melanin production and did not interfere
with the ability of retinoic acid to stimulate melanin production (Figure 6C).
Indeed, the combination of retinoic acid and 2.5 µM bisindolylmaleimide resulted
in an additive stimulation of melanin production.
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Figure 6. Requirement of PKC enzyme activity for RA-induced inhibition of
anchorage-dependent, -independent growth and stimulation of melanin
synthesis. B16 cells were treated with various agents and growth or melanin
levels were measured as described below. A. Anchorage-dependent growth.
Cells were seeded in 60 mm tissue culture dishes at 2.8 × 104/dish. One day
after seeding, cells were refed with growth media containing the indicated
concentrations of RA, bisindolylmaleimide, or a combination of these two agents.
After 48-h of incubation, cells were enumerated using a hemacytometer. The
data are expressed as the mean +/- SEM of triplicate dishes. B. Anchorageindependent growth. Colony formation in soft agarose was performed as
described in the Methods. All layers contained the indicated concentrations of RA,
bisindolylmaleimide, or a combination of these two agents. After 10 days of
incubation, colonies greater than or equal to 300 µm were counted. The data are
presented as the mean +/- SEM of triplicate dishes of cells in soft agarose. No
colonies were formed in the presence of 100 nM bisindolylmaleimide + 1 pM RA.
C. Melanin production. B16 cells were treated with the indicated concentrations
of RA, bisindolylmaleimide, or a combination of these two agents. After 48-h of
incubation, cells were harvested for cell counts and measurement of intracellular
melanin as described in the Methods. The data are presented as the mean +/SEM of triplicate dishes of cells. These experiments were repeated twice with
similar results. * - comparison between control and Bis alone, † - comparison
between RA and RA+Bis. (* P<0.001, † P<0.001))
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Expression of total and phosphorylated PKCα protein in B16 cells: We also
measured the in vivo activation of PKCα in control and retinoic acid-treated B16
cells by using an antibody that specifically recognizes phospho-Thr638, a site
that is autophosphorylated. While retinoic acid induced an 11-fold increase in
total PKCα, it only induced a 2-fold increase in phospho-Thr638PKCα (Figure 7).
This agrees with our previous work in which we found that retinoic acid only
induced about a two-fold increase in the phosphorylation of the MARCKS protein.
Thus there is a large amount of enzymatically inactive PKCα in retinoic acidtreated B16 mouse melanoma cells.

51

Figure 7. Effect of RA on total PKCα protein level vs. amount of
phosphorylated PKCα. B16 cells were treated with 10 µM RA for 48h and then
prepared for Western Blotting as described in Methods. Replicate blots were
incubated with either antibody against total PKCα protein (Upstate Technology)
or antibody that specifically recognizes phosphorylated thr638 PKCα (Cell
Signaling), an indicator of the amount of enzymatically active PKC. The bottom
half of each blot was incubated separately with antibody against GAPDH to
correct for protein loading and specificity of RA-induced changes. Following
development of the signals by chemiluminescence, the relative amount of total
and phosphorylated PKCα was determined by densitometry with correction for
the relative amount of GAPDH in each sample. This experiment was repeated for
two additional times with similar results. C – control, RA – RA treated.
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Effect of phorbol dibutyrate on B16 cells: In contrast to the effect of inhibition
of PKC enzyme activity, down-regulation of PKC by pre-incubation of B16 cells
with phorbol dibutyrate for 24-h prior to addition of retinoic acid, stimulated cell
growth and antagonized the ability of retinoic acid to inhibit cell proliferation (Fig.
8A). Compared to control, PDB treatment increased cell numbers by 40%, 48-h
of RA treatment caused a 50% decrease in cell number, and PDB and RA
together resulted in a 17% increase in cell number. PDB also enhanced
anchorage-independent growth and interfered with the ability of retinoic acid to
decrease colony formation in soft agarose (Fig 8B). Compared to control, 10 pM
of RA treatment induced an 80% decrease of colony formation in soft agarose,
100 nM PDB treatment alone caused a 2-fold increase, and RA and PDB
treatment together resulted in a significant increase in colony formation. As
previously reported (Niles et al., 1996), down-regulation of PKC via chronic
phorbol dibutyrate treatment inhibited melanin production and antagonized the
ability of retinoic acid to stimulate melanogenesis (Fig. 8C). Compared to control,
PDB treatment induced a 40% and 50% decrease of medium and cellular
melanin production respectively. PDB antoganized RA induced increase of
melanin production. Melanin content in RA+PDB treated cells were significantly
lower than the control, and not significantly different from PDB treated.
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Figure 8. Phorbol dibutyrate antagonizes the biologic effects of RA on B16
melanoma cells. B16 cells were treated with various agents and growth or
melanin production was measured as described below. A. Anchorage-dependent
growth. Cells were seeded in 60 mm tissue culture dishes at 2.8 × 104/dish. One
day after seeding, cells were refed with growth media containing the indicated
concentrations of RA, phorbol dibutyrate, or a combination of these two agents.
In the latter case, phorbol dibutyrate was pre-incubated with the cells for 24-h in
order to down-regulate PKCα before the addition of RA. After 48-h of incubation,
cells were enumerated by hemacytometer counting. The data are expressed as
the mean +/- SEM of triplicate dishes of cells. B. Anchorage-independent growth.
Colony formation in soft agarose was performed as described in Methods. All
layers contained the indicated concentrations of RA, phorbol dibutyrate, or a
combination of these two agents. In the combination treatment, cells were pretreated with 100 nM phorbol dibutyrate in monolayer culture for 24-h before
placing cells in the suspension culture with the RA+PDB combination. After 10
days of incubation, colonies greater than or equal to 300 µm were enumerated.
The data is presented as the mean +/- SEM of triplicate dishes of cells in soft
agarose. C. Melanin production. B16 cells were treated with the indicated
concentration of RA, phorbol dibutyrate, or a combination of these two agents. In
the latter case, phorbol dibutyrate was pre-incubated with the cells for 24-h to
down-regulate PKCα prior to addition of RA. After 48-h of incubation, cells were
harvested for cell counts and measurement of intracellular melanin as described
in Methods. Data is presented as the mean +/- SEM of triplicate dishes of cells.
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These experiments were repeated twice with similar results.

* - comparison

between PDB with or without RA and control; † - comparison of colony formation
between PDB+RA and RA alone. (* P<0.01, † P<0.001)
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Establishment of B16 cells expressing PKCα mutant protein: In light of the
results described above, together with our previous data showing that retinoic
acid induces a 6 to 8-fold increase in PKCα mRNA and protein, we formulated
the hypothesis that PKCα might have non-enzymatic functions in the promotion
of melanoma cell growth and differentiation. To test this hypothesis, we obtained
two types of PKCα mutant constructs from Dr. S. Ohno’s laboratory (Yokahama
City University Medical School, Japan). One construct has a mutation in the ATPbinding site, which renders the encoded protein catalytically inactive. However,
since we were concerned about how the conformation of the mutant protein (it is
unlikely to achieve a mature conformation due to lack of auto-phosphorylation
activity) might affect its ability to interact with other proteins, we obtained a
second construct with mutations in the pseudo-substrate region. The PKCα
encoded by this mutated cDNA would normally be constitutively active, but due
to the second mutation in the ATP-binding site it is still catalytically inactive. B16
melanoma clones stably expressing these mutant PKCα proteins were isolated.
The selection of overexpressed PKCα mutant clones relies on two criteria; first,
overexpression of PKCα protein and second, low PKC specific enzyme activity
despite the overexpression of the protein. This occurs because over-expressed
enzymatically inactive PKCα competes for the binding of PKC substrates by the
wild-type endogenous enzyme, which results in less phosphorylation of PKC
substrate.
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Upon assay, the selected PKCα mutant clones expressed different levels
of PKCα protein (Fig. 9 insert). Clone KR2 has the highest level of PKCα protein,
about 7 times that of the control. Clone RE3 also has higher levels of PKCα
protein, about 5 times that of the control. The PKCα protein levels in clone RE1,
RE2, and KR1 are three, five, and two times that of the control, respectively. The
over-expression of dominant-negative PKCα, either the open-conformation or the
closed-conformation, inhibited the anchorage-dependent and –independent
growth in the B16 cells. Figure 9 shows the amount of immunoreactive PKCα and
total PKC enzyme activity in these various clones. Despite this high expression of
PKCα, these clones have markedly lower PKC enzyme activity than wild-type
cells. Clones KR1, KR2, RE1, RE2, and RE3 meeting the criteria of high PKCα
protein expression, but low PKC-specific enzyme activity, were examined for
their growth and differentiation characteristics.
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Figure 9. Expression of PKCα protein and enzyme activity in B16 clones
transfected with plasmids encoding PKCα mutants. B16 cells were
transfected individually with the plasmids encoding the two different mutant
PKCα cDNAs. Clones were selected for their ability to grow in G418. One
hundred clones were selected and then tested for the total amount of PKCα
protein by Western blotting (insert). These clones were also tested for PKC
enzyme activity using the Amersham kit as described in Methods. Positive clones
were identified as those which expressed higher amounts of PKCα protein
compared to wild type cells and yet had markedly lower PKC enzyme activity
compared to wild type cells. C − contol with no exogenous PKCα; KR − G418
resistant clone containing PKCα protein with single mutation in ATP-binding site;
RE − G418 resistant clone containing PKCα protein with mutation in both the
pseudo-substrate region and the ATP-binding site. PKC enzyme activity is
expressed as pmol

32

P incorporated into the synthetic PKC substrate

peptide/min/mg protein. Positive clones were identified as those which expressed
higher amounts of PKCα protein compared to wild type cells and yet had
markedly lower PKC enzyme activity compared to wild type cells.
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Anchorage-dependent growth in PKCα mutant clones: We found that cells
expressing the mutant PKCα had slower rates of growth than untreated wild-type
B16 cells, there were 36 - 66% decreases in cell numbers at 72-h compared to
the wild-type control (Fig. 10). As a comparison, we treated wild-type cells with
retinoic acid and observed the expected inhibition of proliferation. The growth
rate of retinoic acid-treated cells was similar to the untreated PKCα mutant
clones. In general there was a direct correlation between the growth rate and
PKC enzyme activity, i.e. low enzyme activity = slow rate of growth, and an
inverse correlation between growth rate and PKCα protein level. This suggests a
direct correlation between the level of inactive PKC protein and growth inhibition.
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Figure 10. Anchorage-dependent growth in B16 clones expressing mutated
PKCα proteins. Wild-type B16 cells and clones expressing functionally inactive
mutated PKCα proteins were seeded in 60 mm dishes at 2.8 × 105/dish.
Triplicate dishes of cells were harvested every 24h for a total of 72h. Cell number
was measured by use of a hemacytometer. For comparison to the growth rate of
the clone, wild-type cells were also treated with 10 µM RA and growth measured
as described above. The data is presented as the mean +/- SEM of triplicate
dishes. The entire experiment was repeated three additional times with similar
results. WT-C − wild-type B16 cells treated with DMSO; WT-RA − wild-type B16
cells treated with RA; KR-1, KR-2 − clones expressing PKCα with mutation in the
ATP-binding site; RE1-3 − clones expressing PKCα with mutations in both the
ATP-binding site and the pseudo-substrate region. (* P<0.01)
A. Growth curves of PKCα mutant clones with single mutation.
B. Growth curves of PKCα mutant clones with multiple mutations.
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Anchorage-independent growth in PKCα mutant clones: B16 cells, like most
invasive tumor cells, have the ability to grow in an anchorage-independent
fashion. This is most conventionally measured by the number of spherical tumor
colonies formed in soft agarose. This particular phenotype is very sensitive to
inhibition by retinoic acid. As can be seen in Figure 11A, except for clone RE1,
there was a direct correlation between the number of soft agarose colonies in the
PKCα mutant clones vs. wild type cells and their PKC enzyme activity (Fig. 9). In
contrast, there was an inverse correlation between the number of soft agarose
colonies in the PKCα mutant clones vs. wild-type cells and the relative amount of
PKCα protein (Fig. 11). The clone RE1 was retested and found to have lost the
expression of the mutant PKCα, i.e., its PKC enzyme activity was similar to wildtype cells (Fig. 11B). Therefore, the PKC enzyme activity of these clones was
measure periodically to make sure that all the PKCα mutant clones used in the
following experiments had lower enzyme activity compared to that in the wildtype B16 cells.
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Figure 11.

Anchorage-independent growth in B16 clones expressing

mutated PKCα proteins. A. Colony formation in soft agarose. Wild-type B16
cells and clones previously shown to have functional PKCα mutant proteins were
seeded at 5,000 cells/dish in growth medium containing 0.3% agarose over a
base of growth medium containing 1% agarose. The semi-solid phase containing
the cells was overlaid with growth medium, which was replenished every two
days. At the end of 10 days of incubation, the colonies greater than 300 µm were
counted. The data are presented as the mean +/- SEM of triplicate dishes. This
experiment was repeated twice with similar results. B. Re-evaluation of PKC
enzyme activity. Due to the unexpected number of colonies formed by clone RE1,
all the clones and wild-type cells used in A were re-assayed for PKC enzyme
activity using the assay kit from Amersham as described in Methods. The relative
PKC specific enzyme activity of wild-type cells is set as 1.0. Notice that there is a
good correlation between relative PKC enzyme activity and the ability to form
colonies in soft agarose.
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Melanin production in PKCα mutant clones: Retinoic acid treatment of B16
melanoma cells induces a 2-3 fold increase in melanin production. Ectopic
overexpression of PKCα also results in a higher amount of melanin production
(Gruber et al., 1992). However, as can be seen in Figure 12, none of the clones
which expressed mutant versions of PKCα lacking PKC enzyme activity had
higher melanin content than wild-type cells. Three out of four times the medium
melanin produced by clone RE1 was not significantly different from the wild-type
B16 cells. Also treatment of these clones with retinoic acid failed to increase
melanin production, except for KR2, in which retinoic acid increased the amount
of melanin found in the growth medium. These data suggest that PKCα enzyme
activity is involved in RA induced increase of melanin production in B16 cells.
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Figure 12. Melanin production in control and retinoic acid treated wild-type
and PKCα mutant protein expression clones. Wild-type B16 cells and clones
expressing the different mutated PKCα proteins were treated with +/- 10 µM RA
for 48 h. After this incubation, cells were harvested for cell counts and
measurement of intracellular and extracellular melanin as described in Methods.
Data is presented as the mean +/- SEM of triplicate dishes of cells. The entire
experiment was repeated three additional times with similar results. KR-1, KR-2 −
clones expressing PKCα with mutation in the ATP-binding site; RE1-3 − clones
expressing PKCα with mutations in both the ATP-binding site and the pseudosubstrate region. (* P<0.05)
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AP-1 transcriptional activity in PKCα mutant clones: Treatment of wild-type
B16 cells with retinoic acid results in an increase in AP-1 transcriptional activity
(Desai and Niles, 1997). This increase occurs in a slow fashion, but is maintained
for the duration of the treatment period. Recent evidence suggests that this AP-1
activity appears to be required for retinoic acid’s effect on B16 growth arrest and
differentiation (Huang and Niles, 2002). All of the PKCα mutant clones had 2 to 6
-fold increase on AP-1 transcriptional activity as in wild-type B16 cells (Fig. 13).
RA treatment did not significantly increase AP-1 transcriptional activity in the
clones.
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Figure 13. AP-1 transcriptional activity in control and retinoic acid-treated
wild-type and clones expressing mutated PKCα. Wild-type B16 cells and
clones expressing the different mutated PKCα proteins were transfected with an
AP-1-luciferase reporter gene plasmid, together with a gene encoding βgalactosidase to correct the transfection efficiency, as described in Methods.
Transfected cells were treated with +/- 10 µM RA for 24 h, after which they were
harvested and assayed for luciferase and β-galactosidase activity. The data are
presented as the mean +/- SEM relative luciferase activity, corrected for βgalactosidase activity, from triplicate plates of transfected cells.

The PKC

enzyme activities of all these clones were checked to be much lower than that of
the wild-type B16 cells. This experiment has been repeated for two additional
times with similar results. (* P<0.05)
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Effect of overexpression of mutated PKCα on other PKC isozymes in B16
cells: One possible reason for the phenotype seen in clones expressing the
mutant PKCα could be an alteration in the level of activation of other PKC
isozymes. It appears that PDK-1 (Sonnenberg et al., 2001) is required to
phosphorylate most PKC isozymes on the activation loop as the first step in their
maturation. Overexpression of PKCα could potentially sequester the PDK and
prevent it from activating the other PKC isozymes. To examine this possibility, we
measured the amount of total and phosphorylated PKC isozyme, an indicator of
its state of activation (where the two sets of antibodies were available) in wildtype and clones expressing the PKCα mutants. Figure 14 shows that level of total
and phosphorylated PKCδ and ζ was similar in wild-type B16 cells and in clones
expressing either of the two PKCα mutant proteins. Therefore overexpression of
PKCα did not inhibit the phopshorylation of other PKC isozymes.
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Figure 14. Phosphorylation of PKC isozymes in wild-type cells and clones
expressing mutated PKCα. The amount of total and phosphorylated PKCδ
(phospho ser642) and PKCζ/λ (phospho thr403/410) in wild-type B16 cells and
clones expressing mutated PKCα was determined by Western blotting. The
antibody to phospho PKCζ also recognizes PKCλ. The experiment was repeated
twice with similar results.
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Discussion
Retinoic acid is an effective inducer of B16 melanoma growth arrest and
differentiation. We have previously shown that treatment of these cells with
retinoic acid increases the expression of PKCα mRNA and protein (Niles and
Loewy, 1989; Rosenbaum and Niles, 1992) and ectopic expression of PKCα
mimics the phenotype induced by retinoic acid (Gruber, et al., 1992). Interestingly,
treatment of PKCα-overexpressing cells with phorbol ester, such as phorbol
dibutyrate, was not required for the observed phenotype. The comparison
between the highly metastatic B16 mouse melanoma cells and the weakly
metastatic amelanotic B78-H1 melanoma cells by La Porta CAM group (La Porta
and Comolli, 1997) showed that the activity of PKCα is higher in B16 cells than in
B78-H1, without changes in the PKCα expression. Previous studies in this
laboratory showed that retinoic acid treatment enriches the subcellular
distribution of PKCα in the nucleus. Retinoic acid treatment increased the amount
of PKCα associated with nuclei by approximately 15-fold, while phorbol 12myristate-13-acetate (PMA) treatment did not alter the amount of PKCα
associated with the nuclear fraction, and the retinoic acid-induced increase of
nuclear PKCα was much greater than that for total PKCα (Gruber et al., 1995).
These results together with some of our other studies (Gruber, et al., 1995; Niles,
et al., 1996), led us to examine whether PKCα enzyme activity is required to

81

exert its role in the pathway by which retinoic acid induces melanoma
differentiation.
Staurosporine, has been used as a PKC inhibitor in a number of studies,
is very potent in inhibiting PKC enzyme activity but is not selective for PKC. In
contrast bisindolylmaleimide, also termed Go6850 or GF 109203X, is a very
selective

and

yet

potent

inhibitor

for

PKC

(Toullec

et

al.,

1991).

Bisindolylmaleimide inhibited most PKC isozymes, but with a ranked potency of
alpha > beta > epsilon > delta > zeta (Martiny-Baron et al., 1993). The halfmaximal inhibitory concentration (IC50) was in the nanomolar range (8 nM) for
PKCα, while the IC50 for PKCε was 15 times higher (132 nM). Since B16 cells do
not express PKCβ and γ, bisindolylmaleimide can be used as a relative specific
inhibitor for PKCα. Based on the results presented in this study we conclude that
increased PKCα enzyme activity is not required for retinoic acid action since the
selective inhibitor bisindolylmaleimide did not reverse the effect of retinoic acid
on inhibition of anchorage-dependent and –independent growth or induction of
melanin production. Indeed, the PKC enzyme inhibitor, when added to the cells
in the absence of retinoic acid, mimicked the phenotype induced by this retinoid.
These results are consistent with various reports (Arita et al., 1992; Baltuch et al.,
1995; Florin-Christensen et al., 1996) demonstrating that PKCα enzyme activity
is associated with increased growth in several different cell types. Combining
bisindolylmaleimide and retinoic acid further inhibited the growth and induced
melanin production to a greater extent than either bisindolylmaleimide or RA
alone. Since activation of PKCα enhances its degradation process, inhibition of
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the PKCα enzyme activity by bisindolylmaleimide may prolong the half life of
PKCα. This may be the reason that bisindolylmaleimide inhibits the proliferation
of B16 and enhances the action of retinoic acid.
The issue of PKCα enzyme activity in retinoic acid-treated cells was
further examined using a newly available phospho-specific antibody that
recognizes phospho-thr638 in PKCα. Since this site is regulated by
autophosphorylation, it is one measure of in vivo enzyme activity. Our data show
that while retinoic acid induces an 11-fold increase in total PKCα protein, there is
only a two-fold increase in PKCα autophosphorylation, which is in agreement
with the RA-induced increase in phosphorylation of the PKC substrate MARCKS
protein (Gruber, et al., 1995). These data, together with the PKC inhibitor results,
support the conclusion that PKCα enzyme activity is not a crucial component of
the retinoic acid signaling pathway.
Phorbol esters are the most powerful and widely recognized tumor
promoters. The application of nanomolar concentrations of PMA causes > 99%
of initiating mice to develop papillomas, with an average of 14 tumors per
survivor (Yamasaki et al., 1981). Phorbol esters bind to and activate PKC. During
normal signaling processes, PKC is transiently activated by DAG. PMA is a
stronger PKC activator than DAG and, in contrast to DAG, is not rapidly
metabolized by the cell. Investigators (Lu et al., 1998) have shown that the
activation of PKCα, δ, and ε by phorbol esters or diacylglycerol stimulated the
ubiquitination and subsequent proteosomal degradation of these PKC isoforms.
The ubiquitination and degradation appeared as early as 30 minutes after 12-O-
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tetradecanoylphorbol-13-acetate (TPA) treatment, while enzymatically inactive
mutant PKCα was protected from the degradation stimulated by TPA.
Proteosome inhibitors were able to block this PKC degradation and also the
TPA-induced transfomation of cells. The PKCα protein level in B16 cells was
dramatically decreased by a 2-h application of PDB (data not shown). Long term
treatment of B16 cells abolished levels of PKCα but not atypical PKCλ protein
which does not respond to PDB activation (data not shown). Instead, PDB
increased the PKCλ protein level as early as 24-h of treatment. The increase of
PKCλ induced by PDB might be a result of compensation for cPKCs and nPKCs
lost by long term PDB treatment. Treatment of B16 cells with PDB increased their
anchorage-dependent growth rate, increased their ability to form colonies in soft
agarose, and reduced melanin production. If PKCα protein is required for RAinduced differentiation, long term treatment of PDB should reverse the action of
RA. Indeed, our study showed that PDB reversed RA’s effect on inhibiting
anchorage-dependent and -independent growth and stimulating melanin
production (Fig. 8 A-C).
We investigated the effect of decreasing PKCα protein level by taking
advantage of the ability of extended phorbol dibutyrate treatment (24-48 h) to
deplete cells of PKC protein. We initially attempted a more specific anti-sense
PKCα method (Dean, et al. 1996) to achieve this objective. But we were not
successful in obtaining significant reduction in the level of PKCα protein using
either transient or stable expression of the antisense oligonucleotide. The data
published by Zhao et al. (2001) using antisense PKCα in B16 cells showed that
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antisense PKCα inhibited the mannosylerythritol lipid-induced melanin production
in B16 cells, no other phenotype change was reported by this group. In B16 cells,
when PKC was down-regulated, we obtained results opposite to those with PKC
enzyme inhibitors, i.e., the activity of retinoic acid was antagonized. Short term
treatment of cells (2 h) with phorbol dibutyrate prior to the addition of retinoic acid
did not antagonize the activity of this retinoid (data not shown). Brooks et al.
(1993) have previously shown that the growth of melanocytic cells is associated
with down-regulation of PKCα and thus provides an explanation for the
antagonism of retinoic acid induction of growth arrest and differentiation.
Our data suggest that retinoic acid induction of PKCα protein, but not its
enzymatic activity, is important in the signaling pathway leading to growth arrest
and differentiation. However, long term treatment of PDB reduces the protein
levels of all cPKCs and nPKCs, and phorbol esters have other functions.
Because of the relative selectivity of bisindolylmaleimide to PKCα at low
concentrations in vitro, it is hard to monitor its in vivo concentration. More direct
evidence is needed to prove that PKCα protein, but not enzyme activity, has a
role in RA induced B16 cell growth arrest and differentiation. There are no
isozyme-specific PKC enzyme inhibitors available. However, there are several
other approaches one can employ to examine the specific role of PKCα, i.e.,
over-expression of PKCα and down-regulation of PKCα by either dominantnegative PKCα or antisense oligonucleotide of PKCα. This laboratory has used
the approach of over-expression of wild-type PKCα, and showed that overexpression of PKCα mimicked the effect of RA treatment on B16 melanoma cells.
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In order to further investigate the possible non-enzymatic role of PKCα, we
used plasmids encoding two different mutant forms of PKCα. Both of these
plasmids encode enzymatically inactive PKCα, however, one plasmid has
additional mutations in the pseudo-substrate region which should result in a
PKCα protein in the catalytically competent conformation. Clones of B16 cells
expressing either of these mutant PKCα proteins had some, but not all of the
phenotypes found in retinoic acid-treated cells, i.e., these clones had a
decreased growth rate, decreased colony formation in soft agarose and
increased AP-1 transcriptional activity compared to either wild-type cells or
clones that did not express the mutant PKCα proteins. However, clones
expressing the mutant PKCα proteins did not have increased melanin production
relative to wild-type cells.
The numbers of colonies formed by B16 clones expressing mutant PKCα
was greatly decreased compared to the wild type cells; there were very few
colonies detectable in clones KR2 and RE3. The number of colonies formed
seemed to correlate with the total PKCα protein level, or inversely correlated with
the enzyme activity of each clone. Of note, in Figure 11A, a late passage of
clone RE1 had about the same number of colonies as the wild-type B16 cells in
soft agarose, while previous experiments showed that RE1 had a lower number
of colonies compared to the wild-type B16 cells. The cause of this change was
the loss of mutant PKCα through passage, which resulted in the restoration of the
enzyme activity of this clone (shown in Figure 11B). This finding provides indirect
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evidence that a non-enzymatic effect of PKCα protein is responsible for the
inhibition of melanoma B16 cell colony formation in soft agarose.
This inhibition of monolayer growth or colony formation correlated with the
PKCα protein level of these clones (Fig. 9). For example, KR2 and RE3 had the
slowest rate of growth and formed very few colonies in soft agarose; the KR2 and
RE3 clones had higher amounts of PKCα protein than other clones.
Melanin production is cell density-dependent. After B16 cells reach a
critical cell density, melanin production is rapidly increased. The clones
expressing mutant PKCα have different growth rates, and therefore it was difficult
to arrive at the same cell densities among different clones and wild type B16 cells.
The densities of the clones expressing mutant PKCα in Figure 12 were much
greater than the wild-type B16. Even though they were more confluent, the
amount of melanin produced per cell number of the clones expressing mutant
PKCα was not higher than the wild-type B16 cells. Furthermore, RA treatment did
not stimulate melanin production in these clones, as it did for the wild-type B16
cells. These data may indicate that PKCα enzyme activity is required for melanin
production.
Melanin production is a marker of differentiation of B16 cells. The enzyme
that is very important in controlling melanogenesis is tyrosinase. Melanin content
has shown to be correlated with tyrosinase activity but not with protein level
(Iozumi et al., 1993). Alpha-MSH (melanocyte stimulating hormone) stimulates
PKC activity in B16 cells (Buffey et al., 1992), and α-MSH-induced pigmentation
was blocked by depletion of PKC (Park et al., 1996). Long term PDB treatment
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depleted PKCα, which resulted in decreased melanin production (data not
shown).
Increased AP-1 activity is associated with survival and proliferation and is
decreased by retinoic acid in many cell lines. However in B16 cells long term
treatment with retinoic acid increases AP-1 activity, and overexpression of
dominant-negative c-fos, a component of the AP-1 complex, is able to block
retinoic acid-induced growth inhibition and differentiation (Huang and Niles,
2001). Moreover, bisindolylmaleimide slightly increased AP-1 activity in B16 cells
and does not block retinoic-acid induced AP-1 activity (Desai and Niles, 1997).
AP-1 activity is increased in clones with overexpression of mutant PKCα, and
further increased with retinoic acid treatment. These data indicate that retinoic
acid-induced AP-1 activity does not require PKCα enzyme activity.
It appears that the conformation of PKC does not affect the growth rate of
these mutant-expressing clones. Clones expressing mutant PKCα eithr in the
open-conformation or closed-conformation grow slower that wild-type B16 in
monolayer and soft-agarose. There were also no apparent phenotypic
differences between clones expressing these two different mutant PKCα proteins.
There are several possibilities to explain these results. First, PKCα protein
which is induced by retinoic acid could have non-enzymatic functions. It has been
reported that PKC stimulates phospholipase D activity through a non-enzymatic
mechanism (Singer et al., 1996). Also PKC binds to proteins other than
substrates (Diaz-Meco et al., 1996; Mochly-Rosen, 1995). The phenotypes of
clones with overexpression of wild-type PKCα are similar to the phenotypes of
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clones with overexpression of mutant PKCα in regards to anchorage–dependent
or –independent growth, but not for melanin production. The major difference
between these two types of clones is that the PKCα mutant clones lack enzyme
activity. It may indicate that while PKCα enzyme activity is not necessary for RAinduced inhibition of growth, RA-induced melanin production requires PKCα
enzyme activity.
A second possibility is that the PKCα mutants, acting as dominantnegative proteins, could interfere with the maturation or activity of other PKC
isozymes via sequestering PDK or substrate respectively. This could lead to a
phenotype similar to wild-type B16 cells treated with the PKC-selective enzyme
inhibitor bisindolylmaleimide (Fig. 6 A-C). However, using phospho-specific
antibodies, we found that PKCδ, ζ, and λ maturation was not changed as a
function of the expression of the mutant PKCα proteins in the various clones.
Overexpression of PKCα does not alter the immunoreactive protein levels of
other PKC isoforms (δ, ε, η, ζ, µ), similar to findings by several other investigators
(Jansen et al., 2001; Zhao et al., 2001). Also inhibition of PKC enzyme activity
with bisindolylmaleimide led to an increase in melanin production, while
expression of the mutant PKCα proteins did not increase melanin production.
Thus it is uncertain how PKC may be involved in the pathway by which retinoic
acid stimulates melanin synthesis. Despite this uncertainty, it is clear that the
increased PKCα in retinoic acid-treated cells does not require catalytic activity to
mediate effects on melanoma cell growth and differentiation.
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Our data indicate that PKCα enzyme activity is not required for its
inhibitory effects on growth of B16 cells. Further investigation is needed to
determine whether the kinase activity of PKCα functions as a tumor promoter.
Enzymatically active PKCα activates the MAPK pathway, which is responsible for
cell motility, invasion of tumor cells, melanin production and other physiological
responses (Cartwright et al., 2002; Kim et al., 2002; Kim et al., 2003). Short term
PDB treatment (2 h) increases phosphorylated MAP kinases, Erk1/2 and p38,
without a change in their total protein level in B16 cells.
It is possible that the functions of PKCα as a protein and as a kinase are
separated. For example, stimulation of melanin production may be a function of
kinase activity, while suppression of growth may be a function of the protein itself.
Our data support this hypothesis. Sun and Rotenberg (1999) reported that
overexpression of PKCα suppresses proliferation, while increased expression of
PKCα catalytic activity in MCF-10 breast cancer cells increased their metastatic
potential (Sun et al., 1999). These two separate properties might compete with
each other, since activation of PKCα enhances its degradation and results in a
decrease in the level of the protein, and an increased level of enzymatically
immature PKCα protein will compete with activated PKCα for substrates. Our
data suggest that the non-enzymatic function of PKCα mediates retinoic acidinduced growth arrest, while PKCα enzymatic activity mediates phorbol esterinduced tumorigenesis.
There are many studies and clinical trials which have used PKC enzyme
inhibitors or PKCα antisense oligonucleotide as anti-tumor drugs (Cotter, 1999;
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Yuen et al., 2000). Given the fact that activated PKCs (conventional and novel)
are subjected to ubiquitination and subsequent degradation, the data in this
research are not necessarily in contradiction to the studies that activated PKCα is
involved in carcinogenesis induced by phorbol esters. When the selective PKC
inhibitor bisindolylmaleimide was used, similar effects seen with RA-treated B16
cells was obtained, i.e., inhibition of anchorage-dependent, -independent growth
and increased melanin production. Using PKCα antisense oligonucleotides to
treat cancers over-expressing PKCα is a valid approach. However if it is used to
specifically taget at PKCα activity based on tumor promoting agent TPA and
phorbol esters increasing PKCα activity, the antisense PKCα oligonucleotide will
not only inhibit its enzyme activity, but also deplete the PKCα protein, this might
partially explain the mixed results from these studies.
We hypothesize that PKCα interacts with other proteins such as
coactivators. We found by immunoprecipitation a 30 KDa protein which was
associated with PKCα. The amount of this protein was much greater in retinoic
acid-treated B16 cells compared to control. The identity of this protein needs to
be further investigated. One future approach is to explore the identity of PKCα
binding proteins in control vs. retinoic acid-treated B16 cells using the yeast twohybrid system.
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Chapter ΙΙ

The Role of PKCλ and Cell Cycle
Regulators in Retinoic Acid Induced
Growth Arrest and Differentiation
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Introduction
PKC isozymes have diversified functions in relation to cell growth and
other biological functions. I have found that there are seven PKC isozymes
expressed in B16 melanoma cells. PKCα is the only PKC isozyme whose level is
increased by retinoic acid treatment. The levels of PKCλ and PKCµ are
decreased about 50% by 48h retinoic acid treatment. Interestingly, we found that
the amount of PKCλ protein varies with the cell growth rate, i.e., its level
increases with rapid proliferation and decreases with a slower growth rate.
PKCλ/ι and PKCζ are the only two known members of the atypical PKC family. In
contrast to other PKC isoforms, the atypical PKCs can not be activated by
calcium, phorbol esters or diacylglycerol. While the classic and novel PKC
isoforms have been extensively studied, little is known about expression,
regulation, and functions of the atypical PKCs. PKCλ/ι has been implicated in the
control of important cellular functions like cell proliferation, survival, glucose
transport, and establishment of cell polarity. Down-regulation of PKCλ/ι with
antisense oligonucleotides or transfection of a kinase-inactive dominant-negative
mutant severely impairs cell proliferation (Berra et al., 1993) and MAPK
activation (Berra et al., 1995). Various studies have found that PKCλ/ι is involved
in embryogenesis, and its expression decreases in differentiated cells. It has
been reported that the induction of cyclin D1 by oncogenic Ha-Ras requires
PKCλ (Kampfer et al., 2001). However, the function and mechanism of PKCλ is
not well studied, and there is no report on the expression and function of PKCλ in
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melanoma. The link between PKCλ expression and the rate of B16 cell growth
led us to investigate the role of PKCλ in B16 mouse melanoma cell proliferation
by overexpression of PKCλ. We also investigated the changes in cell cycle
regulatory proteins in clones over/under-expressing PKCλ and in B16 cells
treated with retinoic acid.
The cell cycle is divided into several phases, the quiescent phase (G0),
the DNA synthesis phase (S), the mitosis phase (M), and before S phase and
after M phase, there are two gap phases, named G1 and G2, respectively. There
are several check points during the cell cycle. The G1 checkpoint is the ratelimiting step in the cell cycle progression. Once the cell passes the G1 phase, it
is committed to cell division. The cell cycle is precisely regulated and coordinated.
The proteins that are involved in the cell cycle regulation are the cyclin family and
the cyclin-dependent kinases (cdks). The holoenzyme complex contains a
regulatory subunit, the cyclins, and a catalytic cdk subunit. While the levels of
cdks remain constant throughout the cell cycle, the expression of cyclins varies
and they have a periodical pattern during the cell cycle. The major cyclins that
are involved in cell cycle regulation are A-type cyclin, B-type cyclin, D-type cyclin
(cyclin D1, D2, and D3), and E-type cyclin (cyclin E1 and E2). The cyclins
assemble with their catalytic partners and control different stages of the cell cycle.
During G1, the D-type cyclin appears before cyclin E. The cyclin D associates
with cdk4 and cdk6 and its amount increases during G1 progression
(Matsushime et al., 1992; Morgan, 1997). The activation of cyclinD/cdk4 or 6
complex is the rate-limiting step in the G1-to-S phase transition. The E-type
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cyclin accumulation happens in late G1 phase. Cyclin E associates with and
activates cdk2 (Koff et al., 1992). The cyclinE/cdk2 complex is also involved in
the G1-to-S phase transition. Cyclin A regulates cdk2 and cdc2, and the
cyclinA/cdk2 complex is essential for S phase progression. Cyclin B associates
with cdc2 and is involved in mitosis.

Cyclin-dependent kinase inhibitors (CKI’s) block the activity of cyclin/cdk
complexes and prevent cell cycle progression. There are two major CKI families,
the Ink4 (inhibitor of cdk4) family and the Cip/Kip (Cdk interacting protein/Kinase
inhibitory protein) family. P16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d make up
the Ink4 family (Serrano et al., 1993; Hannon and Beach, 1994; Guan et al., 1994;
Hirai et al., 1995). Ink4 proteins compete with D-type cyclins for binding to the
cdks and thereby inhibit cyclin D-associated kinase activity. Ink4 proteins are
expressed in a cell-type specific manner. Of note, p16Ink4a is mutated in
melanoma. Currently, p21Cip1, p27Kip1, and p57Kip2 make up the Cip/Kip
family (Haper et al., 1993; Gu et al., 1993; Koff et al., 1993; Lee et al., 1995;
Matsuoka et al., 1995). These proteins interact with cdk2 and cdk4 and inhibit the
activity of the cyclin/cdk complexes. Cip/Kip proteins preferentially inhibit cdk2 in
vivo.

Retinoblastoma (Rb) protein is one the substrates of cdks. In the absence
of mitogen stimulation, Rb binds to E2F and represses its transcriptional function.
E2Fs are transcription factors that regulate the expression of many genes whose
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products are necessary for the G1/S transition and S phase (Harbour and Dean,
2000). Rb is only able to block the activity of E2F when it is hypophosphorylated.
Rb is first phosphorylated by the cyclin D/cdk4 complex, which induces the
interaction between the central domain and the C-terminal part of Rb, allowing
the cyclin E/cdk2 complex to phosphorylate Ser567, a residue that is normally
inaccessible (Harbour et al., 1999). The hyperphosphorylated Rb releases E2F,
which then activates the transcription of genes that are involved in G1/S
transition and S phase. One of the gene targets of E2F is cyclin E (Geng et al.,
1996). The initial phosphorylation of Rb by cyclin D/cdk4 also disrupts its
interaction with HDAC, thereby relieving the repression of the cyclin E gene and
allowing further progression into S (Zhang et al., 2000). Cyclin D/cdk complexes
also regulate the activity of cyclin E/cdk2 by a second mechanism in that cyclin
D/cdk4 complexes sequester the Cip/Kip cell cycle inhibitors (Sherr and Roberts,
1999). The majority of cyclin/cdk complexes interact with p21waf1, which then
stabilizes the complexes and prolongs their half life. Cyclin D/cdk4 competes with
the cyclin E/cdk2 for binding of p21, thereby releasing the p21 inhibition of cyclin
E/cdk2, allowing cells to progress to S phase. Therefore, the main role of cyclin
D/cdk4 is to activate the cyclin E/cdk2 complex. Knock-in mice in which the cyclin
D1 locus was replaced by cyclin E exons confirmed that absence of cyclin D
negates the activation of the cyclin E/cdk2 complexes (Geng et al., 1999). The
hyperphosphorylation of Rb may be maintained during the S phase by cyclin
A/cdk2.
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As mentioned in the Literature Review, retinoic acid induces G1 arrest in
cells, including cancer cells (Preisler et al., 1992; Mangiarotti et al., 1998). The
effect of retinoic acid on cell cycle is related to its regulation of the cell cycle
regulator proteins. The correlation of PKCλ protein with B16 cell growth rate led
me to investigate the relationship between retinoic acid, PKCλ, and cell cycle
regulator proteins.
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Materials and Methods
Cell Culture: B16 mouse melanoma cells were cultured in a humidified
atmosphere of 5% CO2, 95% air at 37°C in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Grand Island, NY). This medium contained 1 g/l glucose and
was supplemented with 10% bovine calf serum (Hyclone) for most of the
experiments or 10% fetal bovine serum for growth studies with stably overexpressing PKCλ. The medium was also supplemented with 50 units/ml penicillin
G, and 50 µg/ml streptomycin sulfate.

Reagents: All the reagents used in this research were obtained from
Sigma (St. Louis, MO) if not stated otherwise. All-trans-RA was obtained from
Fluka Chemical Company (New York). All experiments involving the use of RA
were conducted in yellow light to prevent photo-oxidation of the retinoids and the
RA in each experiment was freshly made. Retinoic acid, bisindolylmaleimide, and
phorbol 12, 13 dibutyrate were dissolved in dimethyl sulfoxide (DMSO) and
handled in yellow light. Transfer buffer was 2.5% (w/v) Tris, 1.44% Glycine, 0.1%
SDS, and 20% (v/v) methanol. TBS was 20 mM Tris pH 7.6, 0.137 M NaCl, and
0.1% Tween-20. Electrophoresis running buffer was 1.44% Glycine, 0.3% Trisbase, 0.1% SDS. LB (Luria-Bertani) medium (1.0% Tryptone, 0.5% Yeast Extract
and 1.0% NaCl) was dissolved in deionized water, the pH was adjusted to 7.0
with NaOH, the solution was autoclaved on liquid cycle for 20 minutes at 15 lb/sq.
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inch, and ampicillin was added to solution to bring the final concentration to 50
µg/ml after the broth was cooled to 55°C. For LB agar plates, LB medium was
prepared as above, and 15 g/L agar was added before autoclaving, and then
poured into 100 mm plates. When the agar was hardened in the plates, they
were inverted and stored at 4°C.

Cell density measurement by crystal violet assay: Crystal violet
assay is a colorimetric assay that is based on the uptake of crystal violet by
attached cells in each plate. Cells were fixed with methanol: acetic acid (3:1) for
1 hour at room temperature. The fixed cells were washed with 80% methanol and
stained with 0.5% crystal violet for 1 hour. Excess dye was removed by washing
the plates with distilled water. Plates were air-dried and the dye was eluted with
0.7 ml of 10% acetic acid. Aliquots of eluted dye from each plate were transferred
to 96-well plates and absorbance was measured at 575 nm with a Microplate
Bio-kinetics Reader.

Plasmid DNA isolation: Plasmid DNA was isolated using a Mini-prep
Kit from Eppendorf (Brinkmann Instruments, New York). The manufacturer’s
protocol was followed to isolate plasmid DNA.

Transformation: Five to ten nanogram of plasmid DNA or 2 µl of cloning
reaction was used for transformation. DNA was introduced into competent E.coli
cells by heat shock at 42°C for exactly 30 seconds. The competent bacteria were
purchased from Invitrogen.

Stable Transfection of B16 Cells: We transfected B16 cells with
pcDNA3.1. The day before the transfection, B16 cells were seeded at 0.8 million
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per plate. Transfection was accomplished by using Lipofectamine plus reagent
(Life Technologies). For each 100 mm dish, 4 µg of DNA was diluted in 750 µl of
serum free DMEM, and 20 µl of Plus Reagent was added to DNA and mixed.
This mixture was incubated at room temperature for 15 minutes. 30 µl of
Lipofectamine Reagent was diluted in 750 µl of serum free DMEM, and the
precomplexed DNA was combined with diluted Lipofectamine Reagent and this
mixture incubated at room temperature for 15 minutes. Cells on the plates were
washed with PBS to remove residual medium and then 5 ml of serum free DMEM
was added. The DNA-Plus-Lipofectamine Reagent complexes were added to the
plates, which were incubated at 37°C with 5% CO2 for 5 hours. After this
incubation, the volume of medium of each plate was increased to 10 ml and fetal
bovine serum was added at a final concentration of 10%. Neomycin-resistant
clones were selected in DMEM containing 1.43 µg/ml of the neomycin derivative
G418 (Gibco).

Western Blot Analysis: Cells were seeded at 2x105 /100 mm dish and
after attachment (overnight), and they were refed with DMEM containing 10%
fetal bovine serum with or without 10 µM RA. Following a 48-h incubation, the
medium was removed, cells were washed with PBS and lysis buffer added (62.5
mM Tris (pH6.8), 2% w/v sodium dodecyl sulfate (SDS), 10% glycerol, 50 mM
DTT, 0.1% w/v bromphenol blue, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 50 µg/ml
aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, and 0.5% tritonX-100). After
scraping cell from the dishes, the lysates were sonicated for 10 seconds with a
sonic disruptor (Tekmar Corp., Cincinnati, OH) at power setting 60. Cell debris
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was removed by centrifugation at 14,000rpm for 5 minutes. Proteins in the
supernatant were denatured at 100°C for 2 minutes. Equal volumes of cell
extracts were loaded into 10% SDS PAGE and the proteins electrophoretically
separated. The separated proteins were electrically transferred to Hybond-C
Extra nitrocellulose membrane (Amersham). The membrane was incubated for 1
hour in blocking buffer (5% nonfat dry milk in Tris-buffered saline containing 0.1%
Tween (TBST)). The primary antibody was diluted in blocking buffer. The dilution
for monoclonal anti-PKCα, and -PKCδ antibodies (Upstate Technology) was
1:3000. The dilution for monoclonal anti-PKCε, -PKCη -PKCλ, and PKCζ
antibodies (Transduction Laboratories) was 1:400. The incubation time for these
antibodies was 3 hours. The dilution for anti-GAPDH antibody was 1:5000, and
the incubation time was 1 hour. Antibodies for the following proteins were diluted
1:

1000;

Erk1/2,

phosphorylated-PKCα,

p38,

phosphorylated-Erk1/2,

phosphorylated-PKCδ,

phosphorylated-p38,
phosphorylated-PKCλ,

phosphorylated-PKCζ, PKCµ, phosphorylated-PKCµ antibodies, p27Kip1, cyclin
D3, cdk4, cdk6 (Cell Signaling), and p21Waf1 (Pharmingen, CA). All the
antibodies from Cell Signaling were polyclonal antibodies and the incubation time
for these antibodies was overnight. The blot was washed 3 times in TBST
followed by 1-h incubation with a 1:3000 dilution of goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody (Amersham) for monoclonal primary
antibody, or rabbit anti-goat horseradish peroxidase-conjugated secondary
antibody (Cell Signaling) for polyclonal primary antibody. The membrane was
washed 3 times in TBST after incubation with secondary antibody. Reactive

101

bands were visualized by the enhanced chemiluminescence method (Amersham).
All washes and incubations were performed at room temperature. The relative
intensity of each band was measured by a laser scanning densitometer
(Molecular Dynamic, CA).

Monolayer Growth:

Cells were seeded at a density of 2.8x104

cells/60mm tissue culture dish (Falcon) in 3.6 ml of DMEM containing 10% fetal
bovine serum. The medium was changed at the second day and 10 µM RA or
vehicle was added at the same time. Cells were incubated at 37ºC in 7% CO2,
93% air. At 24-h intervals, cells were harvested by trypsinization, and cells were
counted with a hemacytometer.

Colony Formation in Soft Agarose: A 3 ml bottom layer of freshly
prepared 1% agarose/DMEM/10% fetal bovine serum containing the appropriate
RA concentrations was dispensed into 60mm dishes and allowed to solidify. The
top layer consisted of 5000 cells suspended in 3 ml of 0.3% agarose/DMEM/10%
fetal bovine serum containing the respective RA concentrations. Following
solidification of the top layer, a 2 ml DMEM/10% serum liquid overlay, containing
the appropriate RA concentrations, was added to each dish. For experiments
using PDB, B16 cells were grown at monolayer pre-treated with PDB for 24
hours and then transferred to top layer. The liquid phase was changed every 48
h. Viable colonies were counted 10 days after seeding. Only colonies greater
than or equal to 300 µm in diameter were counted.

Relative Melanin Content of Media and Cells: Cells were seeded
into 60 mm dishes so that after 4 days their densities would be similar. After
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attachment, cells were refed with or without 10 µM RA in DMEM. Exactly 3.6 ml
medium was added to each dish. Fourty-eight hours after treatment, 1.5 ml
aliquots of medium were taken from each dish and centrifuged at 12,000 × g for
10 sec. The relative melanin contents of supernatants were determined by
measuring the OD462. 800 µl of 1 N KOH were added to each dish. Cell lysates
were collected and incubated at 80°C for 1 h. The hydrolysates were centrifuged
at 12,000 x g for 10 sec. The relative melanin concentrations of the supernatants
were determined by measuring the absorbance at 462 nm.

Cloning of PKCλ
Isolation of total RNA: Total RNA was isolated from B16 cells using 1
ml of the TRI REAGENT™ per 10cm dish. The mixture was passed several times
through a pipette to form a homogenous lysate. The homogenate was
centrifuged at 12,000 x g for 10 minutes at 4°C to remove the insoluble material.
The homogenate was incubated for 5 minutes at room temperature to ensure
complete dissociation of nucleoprotein complexes. Two hundred-microliter of
chloroform was added to the sample. The mixture was shaken vigorously for 15
seconds, and incubated for 2-15 minutes at room temperature. The mixture was
centrifuged at 12,000 x g for 15 minutes at 4°C. Centrifugation separated the
mixture into 3 phases: a red organic phase (containing protein), an interphase
(containing DNA), and a colorless upper aqueous phase (containing RNA). The
upper aqueous phase was transferred to a fresh tube, 0.5 ml of isopropanol was
added, and this mixture shaken, incubated for 5-10 minutes at room temperature
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and then centrifuged at 12,000 x g for 10 minutes at 4°C. The total RNA
precipitate formed a pellet on the side and bottom of the tube. The supernatant
was removed and the RNA pellet was washed with 1 ml of 75% ethanol. Total
RNA was stored in ethanol at -70°C. RNA samples were centrifuged for 10
minutes at 4°C before use. Ethanol was removed and the total RNA sample was
dissolved in 50 µl of TE buffer (pH 6.8) by pipetting up and down. The total RNA
solution was vortexed for 1 minute and incubated for 10 minutes in a 60ºC water
bath. The total RNA solution was then vortexed for 1 minute and centrifuged
briefly. The concentration of total RNA was determined by the absorbance at
260/280 nm. Reverse transcription was performed using the Advantage® RT-forPCR Kit (Clontech Laboratories, CA). 1 µg of total RNA was added to DEPCtreated water to a total volume of 12.5 µl. The RNA was heated at 70°C for 2
minutes, and then quenched rapidly on ice. 4.0 µl of 5x reaction buffer, 1.0 µl of
dNTP mix, 0.5 µl of Recombinant RNase inhibitor, and 1.0 µl of MMLV reverse
transcriptase (all these were provided by the kit) were added to the RNA solution,
mixed by pipetting up and down, and incubated for 1 hour at 42°C. The reaction
mixtures were heated for 5 minutes at 94ºC to stop the cDNA synthesis and to
destroy any DNase activity. The reaction mixture was diluted to a final volume of
100 µl by adding 80 µl of DEPC-treated water, and then vortexed and centrifuged
briefly. The cDNA was stored at -70ºC.

Polymerase chain reaction (PCR): Primers to amplify murine PKCλ
were designed by the DNA Core Facility at Marshall University. The upstream
primer was 5’ACC ATG TCC CAC ACG GTC G 3’, and the down stream primer
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was 5’CTC TTC TGC AGA CAT CAA G 3’. The primers were designed so that
the cloned gene would be in frame with the sequence from the pcDNA3.1/V5His© TOPO® TA Expression vector used in this cloning, such that the V5 epitope
would be transcribed along with the PKCλ gene. The synthesized primers were
dissolved in TE buffer (pH 8.0) at a concentration of 40 µM. The following
components were placed in a 0.5 ml PCR reaction tube: 25 µl of sterile water, 5
µl of 10xPCR buffer, 1.5 µl of up-stream primer, 1.5 µl of down stream primer, 1
µl of dNTP mix, 15 µl of cDNA, and 1 µl of Ampli Taq®DNA polymerase. Sterile
water was added so that the final volume was 50 µl. The thermal cycling
parameters were 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 3
minutes for 25 cycles, and the final extension phase was 10 minutes at 72°C.
The PCR product was checked by agarose gel electrophoresis, and a single
band between the predicted size of 1,645 bp and 2,000 bp was detected. 2 µl of
fresh PCR product was cloned into the TOPO® vector and then transformed into
chemically competent E.coli following the protocol from Invitrogen Life
Technologies (Carlsbad, CA). Six colonies were picked and cultured in LB
medium. Plasmid DNA was isolated using the Perfectprep Plasmid Mini kit from
Eppendorf AG (Hamburg, Germany). Plasmid DNA was digested by two
separate restriction enzymes BglII and MscI. The reaction product was checked
by agarose gel electrophoresis. Two positive clones with PKCλ in the sense
orientation were selected according to the agarose gel electrophoresis result.
Plasmid DNA was kept at 4°C for temporary use and -20°C for long term storage.
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Sequencing: The cloned PKCλ gene was sequenced at the DNA Core
Facility of Marshall University. DNA sequencing confirmed that the cloned
sequence was identical to the PKCλ gene sequence from the Gene Bank using
multiple alignments.

Agarose gel electrophoresis: Agarose (0.7%) was dissolved in TAE
(tris-acetic acid-EDTA) buffer by boiling. At about 50ºC, ethidium bromide was
added to reach a final concentration of 0.5 µg/ml.

Stable Transfection and Screening: The cloned PKCλ plasmid was
transfected into wild type B16 cells as previously described in part I and G418
resistant clones selected and transferred to 30 mm dishes. Once the cells were
confluent, they were transferred to larger dishes. Western blotting was used to
screen the clones for over-expression of PKCλ. Anti-V5 (Invitrogen Life
Technology) antibody was used to detect the PKCλ/V5 epitope fusion proteins.
For detecting the total PKCλ protein level, anti-PKCλ antibody (Transduction
Laboratory, Lexington, KY) was used.
Statistical analysis: Statistical analyses were performed using one way
ANOVA in SigmaStat™ statistical software (Jandel Scientific; San Rafael, CA).
Statistical significance was judged at the p<0.05 level.
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Results
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Expression of PKC isozymes in B16 cells: Of the eleven members of the PKC
family, there are seven which are expressed in B16 cells. The PKC isozymes
expressed in B16 cells are PKCα, PKCδ, PKCε, PKCθ, PKCζ, PKCλ and PKCµ
(Fig. 15). Of these seven PKC isozymes, the only members whose expression
was altered by retinoic acid treatment were PKCα, PKCλ and PKCµ. PKCα is the
only isozyme that is increased by retinoic acid treatment. The expression of
PKCλ and PKCµ was decreased about 50% by a 48-h retinoic acid treatment.
Since PKCµ is considered by some investigators not to be a member of the PKC
family due to its disparate catalytic sequence, and since we have previously
discussed the role of PKCα in retinoic acid induced B16 cell growth inhibition and
differentiation, the following part of this dissertation will focus on the role of PKCλ
in B16 cell growth and differentiation.
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Figure 15. Expression of PKC isozymes in wild-type B16 cells. B16 cells
were treated with 10 µM RA for 48h and prepared for Western Blotting as
described in Methods. Replicate blots were incubated with antibodies against
total PKCα, δ, ε, ζ, θ, λ and µ proteins. The bottom half of each blot was
incubated separately with antibody against GAPDH to correct for protein loading
and specificity for RA-induced changes. Following development of the signals by
chemiluminesence, the relative amount of PKC isozymes was determined by
densitometry, with correction for the relative amount of GAPDH in each sample.
A. PKC isozymes whose expression is altered by RA. They are PKCα, PKCλ,
and PKCµ. B. PKC isozymes whose expression is not changed by RA. They are
PKCδ, PKCε, PKCζ, and PKCθ. The experiment was repeated twice with similar
results.
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Temporal expression of PKCλ in B16 cells: We studied the expression level of
PKCλ in B16 cells at 24 h, 48 h, 72 h, and 96 h time points treated with or without
retinoic acid after cells were refed with fresh medium (Fig. 16A). In the absence
of retinoic acid, PKCλ protein levels increased with time and peaked at 48h, then
declined at 72 h and reached the lowest point at 96 h (Fig. 16B). Interestingly,
this temporal variation of PKCλ expression correlates with the B16 cell growth
rate. Figure 16C is a semi-logarithmic plot of cell density vs. time. With the
seeding density of 2.8 × 105/60mm culture dish, B16 cells have the highest rate
of proliferation from 24 to 48 h, after which growth slows, and at the 96 h, they
reach confluence. These results led us to hypothesize that PKCλ is involved in
the growth control of B16 cells, possibly through its control of cell cycle regulatory
proteins.
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Figure 16. Time course expression of PKCλ in B16 cells. B16 cells were
seeded in 60 mm tissue culture dishes at 2.8 × 104/dish. One day after seeding,
cells were refed with growth media with or without 10 µM RA. At 24, 48, 72 and
96 hours, cells were prepared for Western blotting as described in Methods. The
blot was incubated with antibody against total PKCλ, and the bottom half of each
blot was incubated separately with antibody against GAPDH to correct for protein
loading.
A. Western blot.
B. Relative amount of total PKCλ determined by densitometry with correction for
the relative amount of GAPDH in each sample.
C. B16 cells growth curve +/- RA. The logarithmic value of cell number at each
time point was plotted vs. the time. The slope between two points represents the
average growth rate between these to two time points. The experiment was
repeated twice with similar results.
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Cloning of full length mouse PKCλ cDNA: In order to study the role of PKCλ in
B16 growth control, we cloned the full length mouse PKCλ cDNA into
pcDNA3.1/V5-His© TOPO® TA Expression vector (see Methods for details). Total
RNA was isolated from B16 cells and converted to cDNA. Primers specific for
mouse PKCλ were used to amplify the PKCλ. The size of the amplified mouse
PKCλ cDNA is 1754bp (Fig. 17). Because a nonspecific band appeared in the
PCR product of 30 cycles, the PKCλ PCR product of 25 cycles was used for
cloning of PKCλ. Then mouse PKCλ was sequenced and confirmed to have the
identical DNA sequence as the cDNA for murine PKCλ described in Genebank.
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Figure 17. RT-PCR synthesis of full-length mouse PKCλ cDNA. Total RNA
was isolated from wild-type B16 cells and converted to cDNA using an RT-PCR
kit as described in Methods. The cDNA was used as template for PCR using
primers specific for the PKCλ gene. DNA was amplified for 25 or 30 cycles.
G3PDH was used as a positive control for PCR reaction. PCR products were
load in 1% agarose gel. The amplified PKCλ is 1754 bp, located between 1650
and 2000 bp band on DNA ladder.
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Selection of sense orientation of PKCλ cDNA: PKCλ cDNA was cloned into
pcDNA3.1/V5-His© TOPO® TA Expression vector. Two restriction endonucleases,
Bgl II and Msc I were used to select the sense orientation of PKCλ cDNA. Each
restriction enzyme cuts once within the PKCλ cDNA and once in the vector. The
locations of these sites were shown in Figure 18A. If the PKCλ cDNA is in the
sense orientation, restriction enzyme digestion should yield a 2180 bp Bgl II
fragment and a 2844bp Msc I fragment (Fig. 18A). Using these diagnostic
restriction fragments, clone#3 and #4 has the PKCλ in the sense orientation (Fig.
18B).
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Figure 18. Restriction enzyme digestion of plasmid containing full length of
mouse PKCλ cDNA. The PCR product was inserted into pcDNA3.1/V5-His©
TOPO® TA Expression vector as described in Methods. Double restriction
enzyme digestion with Bgl II and Msc II was used to select the plasmid with
PKCλ cDNA in the sense orientation as described in Methods.
A. Diagram of the double restriction enzyme digestion cutting the pcDNA3.1/V5His© TOPO® TA Expression vector containing full length PKCλ.
B. Electrophoresis result of the enzyme digestion by Bgl II or Msc I.
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Screening for clones with B16 cell overexpression of PKCλ: B16 cells were
transfected with plasmid containing mouse PKCλ and G418 resistant clones
were selected for further screening of clones with exogenous PKCλ. The PCR
upstream primer starts 22 bases before the tranlation start site ATG of mouse
PKCλ cDNA, and the down stream primer ends 6 bases before the stop codon,
so the amplified PKCλ could be inserted in frame with the vector DNA sequence
which encodes the V5 epitope. This feature allowed us to select the exogenous
PKCλ using an antibody that recognizes the V5-epitope. Two clones, #12 and
#30 which were V5-epitope positive, were selected as B16 cell clones that
express exogenous PKCλ (Fig. 19A). Total PKCλ protein levels were then
detected by Western blot against PKCλ. The Western blot result confirmed that
clone #12 and #30 overexpressed PKCλ, which is about two-fold increase
compared to wildtype B16 cell. Clone #105, a V5-epitope negative clone, had
lower PKCλ protein level, which is about 70% of the wildtype (Fig. 19B). We used
clone #105 as a negative control in the phenotype study.
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Figure 19. Expression of exogenous and total PKCλ protein in B16 clones
transfected with plasmid encoding the full length mouse PKCλ cDNA. B16
cells were transfected with plasmid encoding the full length mouse PKCλ cDNA
fused with the V5 epitope. Clones were selected for their ability to grow in G418.
One hundred and twenty clones were selected and then tested for the amount of
exogenous PKCλ protein expressed by Western blotting using anti-V5 antibody.
– negative control for V5 epitope expression using cell lysate from B16 cells
transfected with empty vector; + positive for V5 epitope expression using cell
lysate from the in vitro transcription translation system with the plasmid
containing the full length mouse PKCλ cDNA.
A. Expression of PKCλ fusion protein using antibody against V5 epitope.
B. Expression of total PKCλ in the selected clones using antibody against PKCλ.
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Anchorage-dependent growth in PKCλ overexpressed clones: The growth
studies showed that cells expressing the exogenous PKCλ (clone #12 and #30)
had faster rates of growth than untreated wild type B16 cells (P<0.001 and <0.05
respectively). The growth rate of clone #105 which underexpress PKCλ was
slower than the wild type B16 cells (P<0.001). Retinoic acid was able to inhibit
the growth of wildtype and clones that over/underexpress PKCλ. Figure 20
shows the cell numbers of these clones at 72 h in the presence or absence of RA.
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Figure 20. Anchorage-dependent growth in B16 clones over or underexpressing PKCλ proteins relative to wild-type cells. Cells were seeded in 60
mm dishes at 2.8 × 105/dish. Triplicate dishes of cells were harvested at 72 h.
Cell number was measured by using crystal violet dye release described in
Methods. The data is presented as the mean +/- SEM of triplicate dishes. The
entire experiment was repeated two additional times with similar results. #12, #30
- clones overexpressing PKCλ; #105 – clone with low PKCλ protein level relative
to wild-type cells. (* P<0.05)
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Anchorage-independent growth in PKCλ overexpressed clones: We
determined whether altered expression of PKCλ would affect the ability of B16
cells to grow in an anchorage-independent fashion, as measured by colony
formation in soft agarose. As can be seen in Figure 21, clone #105, which has
lower PKCλ protein level relative to the wild type cells, had fewer soft agarose
colonies compared to wild type or clones overexpressing PKCλ. However, there
was no significant difference between the number of soft agarose colonies
formed by wild type cells and the two clones which overexpress PKCλ.
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Figure 21. Anchorage-independent growth in B16 clones over/underexpressing PKCλ proteins relative to wild-type cells. Cells were seeded at
5,000 cells/dish in growth medium containing 0.3% agarose over a base of
growth medium containing 1% agarose. The semi-solid phase containing the
cells was overlaid with growth medium, which was replenished every two days.
At the end of 10 days of incubation, the colonies greater than 300 µm were
counted. The data are presented as the mean +/- SEM of triplicate dishes. #12
and #30 − clones over-expressing PKCλ; #105 − clone expressing lower amount
of PKCλ.

130

Figure 21
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Melanin production in PKCλ overexpressed clones: Melanin production is a
differentiated function of melanocytes, which is frequently decreased or lost in
melanoma, I investigated whether over/under expression of PKCλ would alter
melanin production in these cells. There was little difference in cellular melanin
production between the wild-type B16 cells, clones that overexpressed PKCλ,
and a clone which underexpressed PKCλ. However, the B16 cell clone that
underexpressed PKCλ had 2-fold increase of melanin released into medium
compared to wildtype B16 cells and the B16 cell clones that overexpress PKCλ
(Fig. 22).
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Figure 22. Melanin production in control and retinoic acid treated wild-type
and PKCα mutant protein expression clones. Wild-type B16 cells and clones
expressing the PKCλ proteins were seeded. After 48 h of incubation, cells were
harvested for cell counts and measurement of intracellular and extracellular
melanin as described in Methods. Data are presented as the mean +/- SEM of
triplicate dishes of cells. The entire experiment was repeated two additional times
with similar results. #12 and #30 − clones overexpressing PKCλ; #105 − clone
expressing lower amount of PKCλ. This experiment was repeated twice with
similar results. (* P<0.001)
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Expression of cell cycle regulatory proteins in B16 cells: The discoveries
that PKCλ expression level varies with the B16 cell growth rate, clones
overexpressing PKCλ clones grow faster than the wild-type B16 cells, and that
underexpressing PKCλ grew more slowly led us to investigate the relationship
between PKCλ expression and cell cycle regulatory proteins. The protein levels
of cyclin A, cyclin D1, cyclin D2, cdk4, cdk6, p21, and p27 proteins were
examined in wildtype B16 cells and B16 clones overexpressing PKCλ treated
with or without retinoic acid. There were no consistent changes in the protein
levels of these cell cycle regulatory proteins between the wildtypes B16 cells and
clones overexpressing PKCλ at 48 h. However, there were consistent and large
changes in the levels of p21 and p27 in retinoic acid-treated vs. control cells.
There were no consistent changes in the protein levels of cyclin A, cyclin D1,
cyclin D2, cdc 25, cdk4, and cdk6 between in RA-treated vs. control cells at 48 h.
A 48-h treatment with RA decreased the protein level of p21 by 50%, whereas
the level of p27 was increased by about 2 fold compared to the control cells (Fig.
23).

135

Figure 23. Expression of cell cycle regulatory proteins in wild-type B16
cells. Cells were treated with 10 µM RA for 48h and cell extracts were prepared
for Western Blotting as described in Methods. Replicate blots were incubated
with antibodies that recognize cdk4, cdk6, cyclinD1, cyclinD3, cyclinA, p21
Waf1/Cip1, and p27 Kip1. The bottom half of each blot was incubated separately
with antibody against GAPDH to correct for protein loading and specificity for RAinduced changes. Following development of the signals by chemiluminesence,
the relative amount of each protein was determined by densitometry with
correction for the relative amount of GAPDH in each sample. The experiment
was repeated two additional times with similar results.
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Time course for retinoic acid-induced changes in the expression of p21 and
p27. Analysis of the time dependent changes in expression of p21 and p27
showed that p27 is upregulated by retinoic acid at an early stage (2-4 h) (Fig. 24).
Expression of p21 decreased with time in both control and treated cultures. RA
consistently decreased p21 only at the 48 h treatment time. The earliest time
point of p27 expression change induced by RA is at 2-4 h. The changes seen in
the cell cycle inhibitors were not caused by the change of PKCλ, since RA does
not change the PKCλ protein level until 48 h. It may be possible that PKCλ is the
downstream effector of a growth regulatory protein.
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Figure 24. Temporal expression of p21WAF1 and p27Kip1 in control and RA
treated cells. Cells were treated with 10 µM RA for the indicated times and then
cell extracts were prepared for Western Blotting as described in Methods.
Replicate blots were incubated with antibodies that recognize p21 Waf1/Cip1 (A),
and p27 Kip1 (B). The bottom half of each blot was incubated separately with
antibody against GAPDH to correct for protein loading and specificity for RAinduced changes. Following development of the signals by chemiluminesence,
the relative amount of p21 and p27 was determined by densitometry, with
correction for the relative amount of GAPDH in each sample. This experiment
was repeated twice with similar results.
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Figure 24
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Discussion
In this study, we show that the level of PKCλ protein correlates with B16
melanoma cell growth rate. I also found that retinoic acid down-regulated PKCλ
protein expression. Cells transfected with and overexpressing PKCλ had a higher
rate of proliferation, while a clone of B16 with low expression of PKCλ relative to
wild-type cells had a lower rate of growth. We also found that the amount of cell
regulatory proteins p21 and p27 are controlled by retinoic acid. However, altered
expression of PKCλ did not change the amount of p21 or p27 (data not shown).
It has been demonstrated that the microinjection of a peptide with the
sequence of the pseudosubstrate of the atypical PKCs dramatically inhibits
oocyte maturation (Dominguez et al., 1992), cell proliferation (Berra et al., 1993),
and NF-κB expression (Dominguez et al., 1993). However, up until this present
study there were no reports demonstrating that overexpression of PKCλ affects
cancer cell growth.
Dr. Ohno’s group first discovered PKCλ in mouse P19 embryonal
carcinoma cells, where this isozyme is abundantly expressed (Akimoto et al.,
1994). They have demonstrated that PKCλ is expressed ubiquitously, while the
other atypical PKC, PKCζ has a more restricted expression. Moreover, they have
also demonstrated that retinoic acid treatment, which induces the differentiation
of P19 cells, is accompanied by large increases in PKCα and PKCε mRNAs and
decreases in PKCλ and PKCγ mRNAs. We also found similar changes in PKC in
retinoic acid-induced B16 cell growth arrest and differentiation, i.e. the up-
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regulation of PKCα and down-regulation of PKCλ. Several reports found that
PKCλ is involved in activation of AP-1 transcriptional activity, followed by the
activation of the MAPK pathway; hence the proliferation of cancer cells (Bonizzi
et al., 1999; Huang et al., 2000). These pathways need to be examined in our
clones which over/under express PKCλ.
We do not know how PKCλ expression is regulated by retinoic acid. It
could be regulated at the transcriptional level, or posttranslational level. Since the
sequence of PKCλ promoter is not currently available, we do not know if there is
a retinoic-acid response element in its promoter region. We need to investigate
the half life of the PKCλ protein in B16 cells treated with retinoic acid vs. control
in order to determine if retinoic acid regulates PKCλ protein via a posttranslational mechanism.
With the overexpression data and the time course expression profile of
PKCλ, we thought there may be a link between PKCλ and cell cycle regulators.
We examined the expression of cell cycle regulatory proteins in clones which
overexpressed PKCλ. However, there are no consistent changes in the levels of
cyclins, cdks or cdk inhibitors in wild type vs. PKCλ overexpressing clones.
These data may indicate that PKCλ does not directly regulate the cell cycle.
However, we found that retinoic treatment of wild type cells consistently
increased p27 expression and down-regulated p21 expression. Both p21 and
p27 are the members of Waf/Kip cell cycle inhibitor family.
There is a retinoic acid response element in the p21 promoter, and retinoic
acid increases p21 mRNA and protein levels in many cell lines (Lavelle et al.,
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1999; Suzui et al., 2000). However, the down regulation of p21 by retinoic acid in
B16 cells is a consistent finding. I have also found that RA inhibits p21
expression in B16 clones overexpressing PKCλ. Changes of p21 expression
induced by retinoic acid treatment at times earlier than 48-h are not large or
consistent. Immunoreactive p21 appears as a doublet on the Western blot (Fig.
23 and Fig. 24A). It is most likely that the upper band represents phosphorylated
p21. Sheaff et al. (1997) has reported that p27 can be phosphorylated, but there
have been no reports of phosphorylated p21. The nature of this doublet needs to
be investigated by using phosphatase to determine if removing phosphate
collapses the doublet into one band.
Our finding that RA decreases p21 expression in B16 melanoma cells is at
odds with numerous reports showing that RA increases expression of p21. Hsu
et al. (2000) has reported that retinoic acid treatment up-regulated p27 and
down-regulated p21 in human lung squamous carcinoma cells, similar to the
results described above for B16 cells. It is well established that retinoic acid
inhibits B16 cell growth and p21 is a cyclin kinase inhibitor, but the importance of
down-regulation of p21 by retinoic acid treatment is unknown. One possible
explanation is that p21 is mutated in the B16 cell line as a result of carcinogenic
process. Mutations in the p21 and p27 genes are rare (Nakayama et al., 1996)
and the most often seen mutations in CKIs are the mutations of p16 genes, as
found in familial melanomas and other cancers (reviewed by Sherr and Roberts,
1999). However, p21 has been shown to have polymorphisms in sporadic
melanoma within the Japanese population (Konishi et al., 2000). Moreover, p21
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is highly overexpressed in human squamous cell carcinomas compared to
adjacent benign epithelium (Tron et al., 1996), and its expression is increased in
advanced primary melanomas compared with benign lesions such as common
acquired nevi (Trotter et al., 1997). High levels of p21 are associated with chemo
resistance in myelogenous leukemias (Zhang et al., 1995). The significance of
high levels of p21 in melanomas is not clear. If overexpression of p21 is
associated with the melanoma phenotype, then a decrease in melanoma cells
which lose this phenotype, such as RA treated cells would be a logical finding.
Another possible explanation is that p21 interacts with cyclin D and stabilizes the
complex (Cheng et al., 1999). A decrease in p21 induced by retinoic acid may
destabilize the p21-cyclin D complex, thereby interfering with cell cycle
progression. Further studies need to be done to explore the importance of this
reduction of p21 by retinoic acid in B16 cells. Lastly, there is a reciprocal
relationship between p27 and p21, in that an increase of p27 is associated with a
decrease of p21 (Matyak et al., 1999; D’Agnano et al., 2001).
An increase in the level of p27 protein subsequent to treatment with
retinoic acid has been reported for several cell lines and tumor cell types (Hsu et
al., 2000; Zhang et al., 2001; Nakamura et al., 2003). Most of the studies found
that the RA-induced increase in p27 was independent of the retinoic acid
receptor. However, in one study it was reported that introduction of RAR induced
the expression of p27 (Hayashi et al., 2001). Previous reports showed that p27
mRNA levels were not changed by retinoic acid treatment, whereas the
degradation of p27 through the ubiquitination pathway is decreased by retinoic
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acid treatment. It is likely that the increase of p27 inhibits the ability of cyclin-cdk
complexes to phosphorylate the Rb protein. Hypophosphorylated Rb will prevent
cells from entering into the S phase of the cell cycle. The earliest time point that
an increase of p27 protein is seen is 2-4h after retinoic acid treatment,
suggesting that p27 is directly regulated by retinoic acid. We will need to
determine p27 mRNA levels and the half-life of the p27 protein in control vs. RA
treated cells to gain further insight into how RA regulates p27 expression.
PKCλ/ι protects human K562 leukemia cells against taxol-induced
apoptosis (Murray and Fields, 1997). Phosphorylation of ATF-2 a member of AP1 family, which is required for activity, was significantly reduced after 48-h of
retinoic acid treatment (Huang and Niles, unpublished data). High expression of
ATF-2 renders melanoma resistant to chemotherapeutic drugs, such as taxol
(Hayakawa et al., 2003). We found the phosphorylated ATF-2 level was higher
in clones overexpressing PKCλ compared to a clone underexpressing PKCλ
(data not shown). Additionally, phospho-Erk1/2 was also increased in PKCλ
overexpressing vs. underexpressing clones. These data indicate that PKCλ may
increase cell proliferation via activation of the MAPK pathway. Also PKCλ
overexpression

increases

ATF-2

phosphorylation,

which

may

result

in

maintenance of cell survival and resistance to drug induced apoptosis.
Recent studies have elucidated the important role of PKCλ in the
establishment or maintenance of cell polarity (Suzuki et al., 2001; Nagai-Tamai et
al., 2002). This function of PKCλ might be related to the much higher amount of
melanin released into the medium from the PKCλ underexpressing clone despite
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their low cell density. PKCλ appears to be important in maintaining tight junctions
and cell-cell adhesion.
PKCλ and PKCζ are both members of the atypical PKCs and have
common structures and functions. Both are involved in cell skeleton, however,
PKCζ knock-out mice are viable showing impaired NFκB signaling and immune
response (Leitges et al., 2001; Martin et al., 2002), whereas PKCλ/ι knock-out
mice die at an early embryonic stage (Akimoto et al., unpublished result).
Overexpression of PKCι (the human homolog of PKCλ) leads to increased
resistance to okadaic acid-induced apoptosis, whereas overexpression of PKCζ
has no protective effect (Murray and Fields, 1997). Retinoic acid only downregulates PKCλ, not PKCζ, which indicates that these two members of aPKCs
have different functions.
Retinoic acid up-regulates PKCα and down-regulates PKCλ expression.
Also overexpression of PKCα inhibits B16 cell growth while overexpression of
PKCλ promotes B16 cell proliferation. These data indicate that PKCα and PKCλ
have opposing actions on B16 cell growth. Weichert et al. (2003), using clinical
ovarian tissue specimens, demonstrated a significant negative correlation of
PKCα level with histopathological grading and a significant positive correlation of
PKCι, the human counterpart of PKCλ, with histopathological grading. PKCι
expression was only detected in primary ovarian carcinoma and recurrent cases,
but not in normal and borderline ovarian tissues. Expression of PKCι correlated
with shorter patients’ survival time. These data suggest that alteration of PKC
isoform expression (decrease of PKCα and increase of PKCι) may be involved in
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the progression of ovarian carcinomas (Weichert et al., 2003). Furthermore, long
term treatment of B16 cells with PDB induces increased cell growth and
decreased melanin production (see part I of thesis), while it down-regulates
PKCα and upregulates PKCλ (data not shown). A 24-h treatment of B16 cells
with PDB substantially increases the PKCλ protein level. Whether the increase of
PKCλ by PDB is directly linked to the decrease in PKCα is not known and these
possibilities are currently under investigation.
We tried to further investigate the role of PKCλ in B16 cell proliferation by
expressing a dominant-negative PKCλ mutant. However, transfection with this
construct did not yield any G418 resistant colonies. These results suggest that
PKCλ might essential for B16 cell proliferation. In future study, a conditional
expression vector will be used for the dominant-negative PKCλ to circumvent this
negative selection problem.
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Summary and Conclusions
Retinoids have been used in many clinical trials for prevention and
treatment of certain types of malignancies. The toxicity and resistance of some
tumors to retinoids make it necessary to investigate the mechanism of retinoids’
action in order to develop more effective strategies for chemo-prevention and
treatment of tumors. Retinoic acid induces B16 melanoma cell growth arrest and
differentiation. The expression pattern of the PKC isozymes in these melanoma
cells is changed by retinoic acid. PKCα level is increased 8-12 fold, while PKCλ
expression is decreased by 50%. Overexpression of PKCα and PKCλ increases
or decreases the growth rate of B16 cell respectively, which indicates that these
PKC family members play a role in RA induced B16 cell growth arrest and
differentiation. Discrepancies between the level of PKCα protein and its
associated enzyme activity led us to investigate the possible role of nonenzymatic effect of PKCα.
From the work on PKCα, the conclusions are:
1. Decrease in PKCα enzyme activity by bisindolylmaleimide treatment does
not counteract the action of retinoic acid in B16 cells.
2. Down-regulation of PKCα protein by phorbol dibutyrate does counteract
the action of retinoic acid in B16 cells.
3. Overexpression of dominant-negative PKCα mimicks retinoic acid’s action
on growth arrest and induction of AP-1 activity.
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4. Over-expression of dominant-negative PKCα does not alter the expression
and activity of other PKC isozymes expressed in B16 cells.

From the work on PKCλ, the conclusions are:
1. The PKC isozymes expressed in B16 cells are PKCα, δ, ε, ζ, λ, and µ.
2. PKCα is the only PKC up-regulated by RA, and RA treatment downregulates PKCλ and PKCµ in B16 cells.
3. The expression level of PKCλ correlates with B16 cell growth rate, i.e., the
higher the growth rate, the more PKCλ expressed.
4. Overexpression of full length wild type PKCλ increases B16 cell growth
rate.
5. Cell cycle regulatory proteins are not altered by overexpression of PKCλ.
6. Retinoic acid treatment down-regulates p21 and up-regulates p27
expression in B16 cells.
7. Down-regulation of p21 is a delayed response to RA and upregulation of
p27 is an early response to RA.
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Future Study

Although our work on PKCα indicates that PKCα has non-enzymatic
functions, more work needs to be done to prove this hypothesis. Since we failed
to down-regulate PKCα by using antisense RNA, we can use the siRNA method
to accomplish this goal. This technology has been demonstrated to be a more
effective approach to down-regulating a specific protein. The most direct way to
prove that PKCα has a non-enzymatic function is to identify the proteins that
PKCα interacts with in the nucleus. This goal can be accomplished by using a
yeast two-hybrid system to identify PKCα binding partners.
There have been few published reports on the regulation and function of
PKCλ. I was the first investigator to demonstrate a connection between PKCλ
and retinoic acid. It will be important to determine how retinoic acid regulates
PKCλ expression, and the role of PKCλ in the RA-induced signal transduction
pathway. Use of a cDNA construct encoding dominant-negative PKCλ will allow
us to determine the role of PKCλ in growth. In preliminary studies, clones
expressing DN-PKCλ did not survive. To circumvent this possible lethal effect of
DN-PKCλ, future studies will use the conditional expression approach to study
the role of PKCλ.
Other aspects that need to be clarified regarding the function of PKCλ and
cell cycle regulators include:
1) The relation between PKCλ and MAPK pathway.
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2) Half life of the p21 and p27 protein in control vs. RA treated B16
melanoma cells.
3) Activity of cyclin/cdk complexes in control vs. RA treated B16 cells.
4) The importance of RA-induced down-regulation of p21 in the control of
B16 cell proliferation RA treatment.
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